University of Connecticut

OpenCommons@UConn
UCHC Graduate School Masters Theses 2003 2010

University of Connecticut Health Center Graduate
School

June 2006

Primary Prevention in the 21st Century : A Dollar
of Smoking Cessation
Robert S. Goldsmith

Follow this and additional works at: https://opencommons.uconn.edu/uchcgs_masters
Recommended Citation
Goldsmith, Robert S., "Primary Prevention in the 21st Century : A Dollar of Smoking Cessation" (2006). UCHC Graduate School
Masters Theses 2003 - 2010. 126.
https://opencommons.uconn.edu/uchcgs_masters/126

Primary Prevention in the 21 st Century"

A Dollar of Smoking Cessation
Robert S. Goldsmith

B.S., University of Massachusetts, 1978

M.D., Albert Einstein College of Medicine, 1985

A Thesis Submitted in Partial Fulfillment of the Requirements
for the Degree of Master of Public Health

At the University of Connecticut
2006

Approval Page

Master of Science Thesis

Primary Prevention in the 21 st Century"
A Dollar of Smoking Cessation

Presented by
Robert Stacy Goldsmith, M.D.

Major Advisor

John D. Meyer, M.D. MPH
Associate Advisor

Timothy F. Morse, Ph.D. CPE
Associate Advisor

Raymond J. Fabius, M.D.

University of Connecticut

2006

Preface

My parents, despite advancing age are in wonderful health. Dad, at 86,
still works as an upholsterer. My appreciation of their vitality is heightened by the

experience of a close personal friend whose father is in the last stages of both

small cell and non-small cell lung cancer.

While it is simplistic to attribute my

parents’ relative good health to smoking cessation alone, it is impossible to avoid
the observation that they quit cigarettes decades ago, while our friend’s father

continued.

remember my parents receiving 4 cigarette sample boxes of

Salem’s unsolicited in the mail. They don’t recall any specific moment when they
decided to quit, but, but were somewhat ahead of their peers in recognizing., the
risk and acting.

As the lag period between smoking and the development of lung cancer
in older Americans comes to a close, there remains a huge opportunity to learn

from their illnesses and decrease this risk to those adults approaching middle

age, our children and generations to follow. This thesis is dedicated to the hope
that more effective tobacco control strategies can be deployed before irreparable

harm comes to more Americans and smokers around the world.
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Section Introduction
But this same poison, steeped India weed
In head, hart, lunges, do the soote and cobwebs breede
With that he gasp’d, and breath’d out such a smoke
That all the standers by were like to choke.-Samuel Rowlands,

16011

The totality of healthcare resources in the United States is a relatively
finite entity, limited by government expenditures, insurance payment pools,

employer budgets and individual savings. Within this universe are competing
forces such as the needs of public health to respond to common, communicable
and preventable disease, and the expense of patient care for clinical illness and

injury. The relative balance dictated by American society between these has
varied with innovation, epidemiology of disease, availability of care, political

influences, and in no small measure, commercial interests. This thesis will
examine the relationship between a public health prevention effort, smoking

cessation, and patient care for one of smoking’s sequelae, lung cancer. It will

analyze the effectiveness of both approaches as a function of survival and cost
reduction.

The emergence of public health and patient care
Before the eighteenth century, epidemics such as plague, cholera, and

smallpox evoked only limited public health efforts. The lack of understanding of a
scientific basis of infection promoted a culture that routinely blamed disease on

Borio, G. Tobacco Timeline: The seventeenth century-the great age of the pipe.
Tobacco.org-news and information, www.tobacco.orq/resources/history/Tobacco History

17.html

moral impurity and relied on hope and prayer for survival. This is not to imply
that public health did not exist prior to the 1700’s. Efforts date at least to the

Greek and Roman era. In France in 1350 King John II instituted sanitation
ordinances among other reforms which provided that, "hogs should not be kept in

the cities; that streets should be cleansed, and the offal removed; that butchers

should not sell meat more than two days old in winter and one and one-half in

summer and that fish should be sold the same day they were caught".

It may be argued that the first Golden Age of public health began in 1796
and that eight-year-old James Phipps was its herald. In that year Edward Jenner
inoculated the child with an extract of pus from a cowpox-infected individual.

Subsequently, Phipps was exposed to variola, but did not contract the disease.
With this success, the science of primary prevention was born.

An early milestone in population-based disease management was the
discovery of the communicable nature and infectious origin of cholera by John

Snow and his contemporaries. These revelations formed a basis for modern
epidemiology and the application of sanitation to public health practice 3’ 4. In
America, the birth of the modern public health movement may have occurred with

the publication of Lemuel Shattuck;s Report of the Massachusetts Sanitary
Commission, an extraordinary analysis of the relation of sanitation to morbidity
Shattuck, L. et. al. Report of the Sanitary Commission of Massachusetts 1850. Dutton
Wentworth State Printers, Boston. 1850 page 5.
http ://www. d eltaom eqa. o r.q/s hatt u c k. pdf
3

Smith, G.D., Commentary: Behind the Broad Street Pump: aetiology, epidemiology and
prevention of cholera in mid-19th century Britain. Intl. J. Epidem. 31:920-932. 2002.

4

Snow, J. Snow on Cholera. The Commonwealth Fund. New York. 1936

and declaration of the responsibility of government to provide a public health

infrastructure. Other dramatic advances in public health were the development

of a rabies vaccine by Pasteur in 1885, and the principle of antitoxins by van

Behring and Kitasato at the turn of the century. The latter part of the 19th century

was marked by a change in attitude described as "a great sanitary awakening",
the identification of filth as both a cause of disease and a vehicle of transmission,
and the ensuing embrace of cleanliness. These advances brought the power of
disease control to light and generated trust and reliance on public health for

protection from disease.

The Spanish flu epidemic of 1918 highlighted both the opportunity and
limitation of the public health capabilities of the time. Despite truly global efforts

at quarantine and vaccination, somewhere between 25-40 million deaths
occurred, 675,000 in the United States alone. A golden era had ended.

At the same time that limits to the effectiveness of public health interventions
were realized in the first quarter of the 20th century, medical treatment of ill
individuals began to emerge as a legitimate and powerful approach to

healthcare. There is no single point where the application of disease

management eclipsed the role of prevention in America, but by mid century there
was clearly a greater reliance on individual care than population-based
intervention. Several key discoveries and applications contributed to this trend,

including:
The purification of morphine and quinine in the 19 th century
5

Institute of Medicine. The Future of Public Health. National Academy Press,
Washington, D.C. 1988. page 58

The first application of X-ray imaging in 1895 (Roentgen)

Synthesis of acetylsalicylic acid by Bayer in 1897
The first electrocardiogram, introduced at Presbyterian Hospital, Chicago,
1913

The discovery of a pancreatic enzyme capable of controlling diabetic

hyperglycemia in 1920 and the first use of insulin in 1922.
Isolation of penicillin in 1929 and the earliest use of antibiotics between

1935 and 1940

Although the influence of public health may have waned in the 20th century,
the advancement and application of public health principles did continue, both in
the U.S. and abroad. The eradication of smallpox and advances against polio

were absolute highlights in global medical history. Another prime example was
the global suppression of malaria after the Second World War. These
achievements underscored several aspects of public health initiatives during that

era. For one, the greatest successes were seen in underdeveloped or relatively
impoverished regions. This was due both to the magnitude of public health and
sanitary need and the lack of available medical care.

It is possible, in fact, that

even today, the age of patient care has yet to arrive in much of the world, where
a paucity of physicians, limited access to technology, cultural barriers and
inadequate financial resources hinder this advancement. In those regions the

role of public health is extremely different than that in America; it remains the

primary mode of healthcare.

Another lesson learned in the public health efforts of this century was the
influence of politics, budgets and even environmental factors on prevention

efforts. A footnote to the malaria eradication effort was the influence of political,
and social forces on the program. Despite tens of millions of saved lives, the use
of DDT to eradicate mosquitoes is best remembered by the environmental

backlash championed by Rachel Carson in, Silent Spring. Political forces were

more vividly on display in the formation of the public health response to swine flu
in 1978, which led to widespread, unnecessary vaccination and a possible surge
in reported cases of Guillen Barre syndrome.

The United States CDC lists these ten great public health achievements

"

in the 20 century, and promotes them as a significant cause for the 25-year

improvement in life expectancy in this country.
Immunizations

Motor vehicle safety
Workplace safety
Control of infectious diseases
Declines in deaths from heart disease and stroke

Safer and healthier foods
Healthier mothers and babies
The development and deployment of DDT saved countless millions of lives. In India, for
example, malaria deaths went from nearly a million in 1945 to only a few thousand in
1960.
6

7

Kolata, G. Flu. Simon & Schuster Publishing. 1999. 151-185

Ten Great Public Health Achievements in the 20th Century. CDC Office of
Communications. 1999. www.cdc.qov/od/oc/media/tengpha.htm

Family planning
Fluoridation of drinking water
Identification of tobacco as a public health hazard

These extraordinary achievements help demonstrate the viability of
prevention programs, even during times of exponential advances in surgery,

radiology and pharmacology, and will serve as the foundation for re-emergence
of population-based efforts for the next generation.

The second half of the last century saw the emergence of a new threat to
the public’s health, the long-term effects of tobacco use. Within decades of the

adoption of cigarette smoking as a socially acceptable and popular habit, the
number of cases of lung cancer and chronic obstructive pulmonary disease
increased dramatically. The frequency of these diagnoses may have plateaued
in parallel with per capita U.S. tobacco consumption. These trends are displayed
in figures 1-2. 8,

9. It is both intriguing and unfortunate to note that the decrease in

smoking prevalence has leveled since 1995. Might the incidence of smokingrelated cancer and cardiopulmonary disease reflect that limit within the next
several decades?

8

National Cancer Institute SEER Data. http://seer.cancer..qov/

9

Tobacco Use: United States, 1900-1999. Oncology. 13(12). 1999.

Patient care and the concept of therapeutic plateau

A theory of therapeutic plateau holds that limits exist to the effectiveness
of chronic disease management. As medical progress continues, the
incremental improvement in outcome slows until the rate of change becomes

relatively insignificant. There are three likely scenarios that help define
therapeutic plateau. These may be described as follows:
1. illness is refractory to therapy-There are human diseases that have not

and do not respond well to surgical, medical, or other forms of treatment.

Improvement in outcome for these illnesses may be graphed as a
relatively horizontal line when viewing outcome as a historical function.
2. The illnesses may become refractory to treatment. An example of this

phenomenon is the emergence of antibiotic resistance among several
species of pathogenic bacteria. Limits may also result from the relative
toxicity of treatment.
3. Illness is very responsive to a therapy-In this case a statistical limit to

favorable outcome (cure, remission, survival, disease-free period) creates

a plateau. Almost invariably, there will be limits to successful treatment.
Despite the generally favorable outcome for many illnesses, some

minority of patients will be poor responders, either due to late stage at
diagnosis, inadequacy of treatment, intolerance of therapy, comorbidity,

genetic predisposition, or unusually refractory disease.

In many cases, therapeutic plateaus are temporary phenomena.
Dramatic new medical advances, which invigorate treatment protocols, are

constantly reported. New fields, such as molecular biology, genetic
engineering and immunotherapy will perpetuate outcome improvement for

many diseases. Nonetheless, improvement in the health of a population as
a function of advances in patient care may not be possible or indefinitely
sustainable for any disease state. It is also critical to note that the availability

of a physical cure does not relieve the patient of the anxiety associated with

diagnosis, discomfort, expense, adverse reactions and inconvenience related
to treatment, loss of productivity, and concern for recurrence or second
primary recurrence of illness.
This limit of therapeutic plateau may be cause for reappraisal of

alternative or additional strategies, such as primary prevention. This thesis
will question whether a therapeutic plateau currently exists for lung cancer,

and whether the limited effectiveness of cancer treatment should drive an

emphasis on population-based smoking avoidance and smoking cessation

programs.

Cost of care
Can the amount of money available for patient care continue to support
the volume and types of treatment available? Are there cost savings associated
with primary prevention that are meaningful to the health of Americans? The

answer to these questions is critical in planning American healthcare strategy.

The recovery of the actor Christopher Reeve provides context for these
questions. Prior to his death Mr. Reeve made unprecedented (and to some

observers unexplainable) rehabilitation progress from an equestrian accident that

left him quadriplegic. Despite a prognosis of nil recovery, he regained sensation
and modest motor function in both his upper and lower extremities. His recovery
st
argued strongly for accelerated research and implementation of 21 century

technology for spinal cord injuries. Lost in the clinical scenario, however, was the
cost. Mr. Reeve became relatively ventilator independent as result of
implantation of an intra-diaphragm pacing device, a procedure which was neither

widely available nor insurance reimbursable. He used an electrical stimulation
bike which cost roughly $100,000, and was supported by a team of 18 healthcare

professionals. The cost of his care exceeded five hundred thousand dollars a

year, two-thirds of which was covered by health insurance.

An extremely

difficult decision is whether these extraordinary resources ultimately detract from

those available to the population, either by service limitations or affordability of
insurance, and whether a greater good might be achieved by applying those

funds toward the prevention of similar spinal injuries (via seat belt compliance

measures, water safety courses and helmet promotion programs, for example).

Even without broad application of the intensive rehabilitation services utilized by

Mr. Reeve, car wrecks, debilitating falls and other accidents in the United States

0

Groopman, J. The Reeve Effect. The New Yorker. November 10, 2003. pages 82-

93.
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account for $1 17 billion in cost each year, representing 10% of all medical
spending

In the U.S. the cost per case of personal healthcare threatens to choke
accessibility to the most modern, most effective treatments.

This escalation is

due to inflation of medical expenses, the expense of new treatment modalities,
and rates of utilization. Outside the U.S. this burden is clearly being translated
into clinically important gaps in the availability of patient care. Those limitations

include clinically important formulary restrictions for government-sponsored

healthcare plans, limitations on covered diagnoses, and basic unavailability of

necessary medical care.

’

3, 4

It is not farfetched to worry that similar rationing

currently exists in limited form (such as formulary restrictions) and could expand
in the U.S. At present, several states are considering legislation designed to

make "basic-coverage" available to employers and uninsured workers. These

carve outs would be considered in the effort to increase the number of Americans
with some coverage and reduce states’ Medicaid burdens. 15

As private and public funding of patient care increases, the emphasis on
public funding for primary prevention has waned. In fact, the U.S. Centers for
Numbers. Newsweek Magazine. 17. January 26, 2004.
12

Gawande, A. Dispatch from India. NEJM. 349.25. 2003;2383-2386.

The World Health Report, 2000. WHO Publications. 2000.
http ://www. who. nt/wh r2001/2001/archives/2OOO/en/pdf/overview, pdf

14Gill, B., Hewitt, P, and England, R.. China’s Ailing Healthcare and Welfare System.
Global Aging Initiative and Freeman Chair of Chinese Studies, position paper. Center for
Strategic and International Studies http://www.csis.orq/.qai/ChinaHealthcare.p.df. 2003
15

Freudenheim, M. Broader Health Coverage May Depend on Less. The New York
January 20, 2004.

Times.
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Medicare

& Medicaid Services lists public health as only one of 14 categories of

expenditures. ** Opposing this trend are cost-related efforts in the private sector,
where some recognition of the cost-effectiveness of primary prevention is being

documented. It is becoming clearer that the chronic disease burden among
workers could be reduced through prevention programs targeted at the risk

factors associated with the most common disabling conditions.

Although the best available patient care is a noble and worthwhile
objective, it is quite possible that spending on primary prevention of most injuries
and preventable illnesses is of greater value to the U.S population as a whole.
This thesis will examine the economics of primary prevention of lung cancer in

some detail.

Patterns of Illness and Mortality in the 20th Century and Beyond
It would be an overwhelming task to analyze the contribution of patient
care and public health on all illnesses found in the American public. A more
reasonable approach is to focus on the most important causes of morbidity and

mortality facing Americans today and in the future. Mortality causes in the United
16

Centers for Medicare and Medicaid Services: national health expenditures aggregate
amounts and average change, the type of expenditure 1980-2002
http://www.cms.hhs.qov/statistics/nhe/historical/t2.asp.
The 14 are hospital care, physician and clinical services, other professional services,
dental services, other personal health care, home health care, nursing home care,
prescription drugs, other medical products, government administration and net cost of
private health insurance, government public health activities, research, investments, and
construction.
17

Friedman, C. et. al. Assessing the Burden of Disease ’among an Employed
Population: Implications for Employer-sponsored Prevention Programs. JOEM. 46(1).
2004.3-9.

12

States in 1890,1900 and 2000 are provided in table 1. Mortality trends for the
period from 1950-2001 are charted in Figure 3 8,9,0,. It is critical to glean from

the tables that the leading causes of death at the beginning of the 20 th century

were infections. Although their prominence in part
reflected an immaturity of the public interventions of infection control and
immunization, the trend largely speaks to the inadequacies of individual care in

the pre-antibiotic era.

Leading Causes of Death in the U.S., 1890,1900 and 2000
1890
-Consumption
Pneumonia
Infant cholera
Measles

Cancer
Typhoid fever
Di phtheri a

Croup
Bronchitis

Whooping cough
Scarlet fever

1900
.Pneumonia
.Tuberculosis
.Diarrhea and enteritis
.Heart Disease
.Liver Disease
.I nj u ries

-Cancer
.Senility
.Diphtheria

2000
Diseases of the Heart

Malignant neoplasms
Cerebrovascular disease

-COPD
.Accidents
Diabetes mellitus
Influenza and pneumonia
Nephritis, nephrotic
syndorme and nephrosis
-Septicemia

Table

8

Centers for Disease Control and Prevention, National Center for Health Statistics.
National Vital Statistics System and unpublished data, 1997

9

Anderson, RN. Deaths: Leading Causes for 2000. National Vital Statistics Report. CDC
Report, 2002.

20

Health, United States, 2003. National Center for Health Statistics.
http://www.cdc._ov/nchs/products/pubs/pubd/hus/03tables.htm
Richardson, N., Chermayeff, C., and Walker, TK (eds) Medicine’s Great Journey: One
Hundred Years of Healinq. 1992. Callaway Editions, Inc. p. 9.

13

from 28.1 million to 49.7 million in the interval between 1990 and 2020. 22,23 This
increase in the burden of chronic disease is multifactorial and includes an
increase in the prevalence of risk factors such as obesity and physical inactivity,

the latent emergence of disease from decades-old exposures, treatment
improvements and ongoing public health efforts.

Where will mortality trends evolve in years to come? The possible re-

emergence of widespread or epidemic infectious disease cannot be ruled out for
several reasons:

Larger and shifting populations have increased the risk for spread of
disease.

Humans are living in closer proximity to wildlife and livestock than in any
previous period.
Climatic changes have improved the environment for many pathogenic
microbes and their vectors.

Importation of non-native animal species is becoming increasingly

common, introducing non-native pathogens to new territories.
Bioterrorists threaten to release increasingly virulent agents into the
environment.

Health and Health Care 2010: The Forecast, The Challen.qe 2 nd ed.. Institute for the
Future. Josey-Bass Publishers. 2003. p.22.
23

Public Health’s Infrastructure: a status report. Department of Health and Human
Services, page ii. 1999.

15

More likely than the re-emergence of acute illness as a dominant cause of
mortality, however, is the continued pre-eminence of chronic disease. Several
studies have recently reported an alarming trend in the increase of obesity-

related illness and the associated cost. Clearly, diabetes and obesity related
heart disease will continue to plague American society for years to come 4’’6.

The Disability Adjusted Life Year (DALY)is a quantitative indicator of
burden of disease that reflects the total amount of healthy life lost, to all causes,
whether from premature mortality or from some degree of disability during a
period of time..Analysis of disease patterns by DALY’s in a subset of Americans

further demonstrates the burden of chronic disease on the population. A striking
prominence is noted in the Pareto of this data (figure 4). Thirty-eight percent of
the DALY’s were caused by chronic diseases that may in part be prevented by a

single primary intervention, smoking cessationZ. The Global Burden of Disease

Study (GBD) created a model based on disease and injury trends since 1950. In
their model, the leading causes of disability-adjusted life years were (in

descending order)ischemic heart disease, unipolar major depression, road-traffic
accidents, cerebrovascular disease, chronic obstructive pulmonary disease,

lower respiratory infections, tuberculosis, war injuries, diarrheal disease, and

4

Obesity Costs States Billions in Medical Expenses. CDC office of Communications.

2004.
25

Finkelstein, E.A., Fieberlkorn, I.C., and Wang, G. State-Level Estimates of Annual
Medical Expenditures Attributable to Obesity. Obesity Research. 12 18-24. 2004

_6

Mokdad, A.H. et. al. Actual Causes of Death in the United States, 2000. JAMA.
291 (10) 1238-1245. 2004.
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HIV. 7. Certainly the ranking for the United States would differ somewhat from
the global expectation, but those discrepancies would most likely occur at the tail
end of the list, where infectious disease and diseases of childhood are more
prominent. In the U.S. as elsewhere, lifestyle-related chronic disease will
continue to pose the greatest threat. The GBD estimates 8.4 million annual

smoking-related deaths by 2020. This figure is likely within the same magnitude
of the U.S. CDC projection that an estimated 5 million U.S. persons who were
28
aged 0-17 years in 1995 could die prematurely from smoking-related illnesses.

Will American medicine respond with primary prevention through lifestyle
modification or treatment of resultant illness?

27

Murray, CJ and Lopez, AD. Alternative Projections of Mortality and Disability by Cause
1990-2020: Global Burden of Disease Study. Lancet. 1997 May 24;349(9064):1498-504.

28

Projected Smoking-related Deaths Among Youths, United States. MMWR Weekly
Report. November 08, 1996 / 45(44);971-974.
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stated, "Custome Iothesome to the eye, hateful to the nose, harmful to the brain,

dangerous to the lungs and in the black and stinking fume thereof, nearest
resembling the horrible stygion smoke of the bit that is bottomless." Shortly after
publication of the essay, England saw its first tobacco tax. It remains unclear
whether the tax was established as a public health measure or convenient

means to further the wealth of the monarchy. Within years of Counterbase to
Tobacco, other prominent subjects also commented on tobacco its adverse effect

on health. In 1610, Sire Francis Bacon wrote that, "tobacco use is increasing
and that it is a custom hard to quit". 3

These denouncements were certainly not the standard of the period. As
smoking and snuff became increasingly popular, there were, on both sides of the
Atlantic, continuing stories of its health benefits, including reports of a protective

effect against plague.

Through the next centuries, tobacco use in America was transformed
from a personal habit to a social phenomenon and financial pillar. Regional
economies became dependent on the crop, as did the governments that taxed

cigarettes and other tobacco-containing products. The first federal tax on
cigarettes was imposed in 1864. During that period a populist health reform

movement led to the earliest anti-tobacco movement in this country. The efforts

were, however, aimed at moral and hygiene concerns, rather than the health

3o

Key Dates in the History of Tobacco. The Ash Organization.
www.as k. orq. u k/htm I/sc hools/keydates, html.

19

effects of smoking. 31 A milestone in the expansion of tobacco use may be
marked in the invention of machinery to mass produce cigarettes in the mid
1880’s.
The give and take of tobacco use continued into the 20 th century. The

cachet of smoking, established in earlier eras, continued, as did the backlash.
Moralists blasted cigarettes, referring to them as "coffin nails" and

"gaspers".

Henry Ford deemed cigarette smokers unemployable in a 1914 brochure, stating,
’"’Boys who smoke cigarettes we do not care to keep in our employ. In the future
we will not hire anyone whom we know to be addicted to this habit. It is our
desire to weed it entirely out of the factory just as soon as practicable

,,32

Smokers were characterized as criminals, neurotics or possibly drug
addicts. In 1892 the Senate Committee on Epidemic Diseases agreed that

cigarettes were a public health hazard and urged the states to restrict their use.

In 1900 an increase in cancer of the lung was noted, particularly by vital
statisticians. These calculations are generally described as the first scientific
evidence of the relationship between tobacco and chronic disease. 33 Between
1890 and 1930 fifteen states enacted law to ban the sale, manufacture,

3
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possession or use of cigarettes. 34 What changed, however, in the first part of

the last century, was the advent of modern advertising. In 1914 the R.J.

Reynolds Tobacco Company launched its first national marketing campaign, for
Camel cigarettes. Competitors quickly followed. 3

The First World War became another major force for the propagation of

smoking in America. The United States entered the war under the banner of
moral reform, pledging to free the world with an army untainted by alcohol and
prostitution. In that context, smoking among the military was considered a

reasonable allowance 34. Army surgeons praised cigarettes for helping the
wounded relax and easing their pain. After the war’s end, smoking popularity

soared, both by social acceptance and dependence by an ever-increasing

percent of the populace.

It was not until the 1940’s that a reinvigorated anti-smoking campaign
took hold. Different than previous efforts targeting the immorality of smoking,
the new program was based on biostatistics and the newly emerging science of

epidemiology. Although scientific papers preceded, a study by Lombard and
Doering, published in the New England Journal of Medicine in 1928, is generally
credited with the first true application of the scientific method to the risk of

tobacco use. The case-control study demonstrated that smoking was more

34
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common among cancer patients than an otherwise similar cohort of individuals
without malignancy. 36

Early research and the apparent emergence of an important number of
cases of smoking-related illness, prompted further research, including the
landmark prospective studies of Doll and Hill in the U.K. and Hammond and Horn
in the U.S. in the early 1950’s 37’3a Mounting and irrefutable evidence on the

potential for cigarette smoking to induce lung cancer lead to increased public

health scrutiny. In 1957 U.S. Surgeon General Leroy Burney announced that,
"The Public Health Service feels the weight of the evidence is increasingly

pointing in one direction; that excessive smoking is one of the causative factors
in lung cancer’’3. It is of interest and some importance that the Tobacco

Industry Research Committee, representing the scientific findings of tobacco

growers, manufacturers, and warehousers was chartered in the same decade.

A further milestone to the recognition of a public health role for tobacco
control was reached with the first Surgeon General’s report on Smoking and
Health. The report was prompted by, among other concerns, an increase in lung

cancer deaths from 3,000 in 1930, to 18,000 in 1950, 27,000 in 1955, and 41,000
in 1962. The report cited 7,000 studies toward a list of conclusions which

included that the death rate for smokers of cigarettes only, was about 70% higher
36

1989 Surgeon General’s Report: reducing the health consequences of smoking. 1989.
Chapter 1, page 5. http://www.cdc.qov/tobacco/sqr/sr_ 1989/1989SGRChapter1 .pdf
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cigarette tar. Part 1. Cancer Res 1953;13:855

22

than that for non-smokers. Although no specifics were provided, the report also

stated, "Cigarette smoking is a health hazard of sufficient importance in the
United States to warrant appropriate remedial action. ’’33

In the 1960’s the percentage of Americans consuming cigarettes began to
level. Although the reasons are likely multiple and varied, it is clear that the

Surgeon General’s report and supporting research sparked some change in
social attitudes. Since that time a progressively smaller fraction of Americans

have become or remained smokers. This trend is visible in Figure 5 The cause

for this decline is likely multifactorial and includes further enlightenment on the
health effects of cigarette smoke, changes in the social perception of smoking,
the increasing cost of cigarettes and restrictive legislation (Arizona became the
first state to restrict smoking as an indoor air pollutant, in 1973). Some highlights

of the last 30 years include the 1965 Federal Cigarette Labeling and Advertising

Act, the 1988 ban on smoking on domestic commercial airliners, and the 1996

FDA regulations designed to regulate tobacco sales and marketing aimed at
minors 3. It is of some concern, however, that the rate of decline in smoking

prevalence has flattened within the past decade. It remains uncertain whether
continuing avoidance and cessation efforts will re-energize the curve, or whether
a core of incorrigible tobacco users will remain.
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is a relatively recent phenomenon, arising first in Western Countries in the

1930’s, with incidence rates rising sharply in subsequent decades.

Prior to that

time a diagnosis of carcinoma of the lung was a very rare phenomenon,

accounting for <1% of all recorded tumors in one series reported in 1921 "*. It
would be overly simplistic to state that lung cancer did not exist before that time.

"

Prior to the 20 century the diagnosis of lung tumors relied entirely on history and

physical examination. Even after discovery of the roentgen ray, a considerable
period elapsed before its application to diagnostic oncology. Similarly, the

. .

bronchoscope, invented in the late 1800’s was not frequently used for cancer
diagnosis until the 1930’s

By 1933 the reported incidence of lung cancer had

increased to 5-10% of all carcinomas

Between the establishment of smoking

as a social phenomenon and today, the incidence and mortality rates have varied
in parallel with tobacco utilization trends". As suggested above, lung cancer is

unique among all malignancies in having a single, modifiable risk factor that
39
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accounts for a high percentage of cases. Compared to individuals who have

never smoked, cigarette smokers have an overall 20-fold increase in lung cancer
risk. It is currently estimated that up to 8% of all smokers will develop some form

of lung cancer during their lifetimes. 44

State-by-state variations in lung cancer incidence also support the
relationship with cigarette smoking.

As may be seen in figure 7, Kentucky,

which has consistently lead the country in percentage of adult smokers, also has

the highest combined male/female mortality from lung cancer. The smoking

prevalence is more than twice that of Utah, the state at the opposite pole of the

study, and the mortality rate was 300% greater in the years 1996-2000. 4

As might be expected, the risk of lung cancer among smokers
varies tremendously, depending on other related and independent risk factors

including age, gender, duration of smoking, and number of cigarettes per day.
Smokers with chronic obstructive lung disease (COPD) have a higher risk than

those with normal lung function 46’4z. In one analysis among. 18,172 smokers, ten-

year cancer risk ranged from 15% for a 68-year-old man who had smoked two
packs per day for 50 years, to 0.8% for a 51-year old woman who smoked one
44
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their propensity for early metastasis. Thus, squamous cell, adenocarcinoma and

large cell lung cancers all tend to invade locally early in the course of the illness,
with late distant spread, while small cell cancer is most often metastatic at the

time of diagnosis. The incidence of these subtypes are displayed in figure 8

Of

note in the chart is the general trend described previously, where peak incidence
is seen in the years just before the rate of smoking in the U.S. began to decline.

.

The exception is adenocarcinoma, which has continued to increase in frequency

to the present

The trend in adenocarcinoma incidence is likely multifactorial,

including changes in diagnostic standards, number of cigarettes consumed by

smokers, and changes in cigarette inhalation patterns associated with the
introduction of filtered and low tar products over recent decades. It is postulated

that smokers of filtered and low tar-low nicotine cigarettes inhale more deeply,

exposing deeper lung regions to these carcinogens. Adenocarcinomata of the

lung are primarily peripheral lesions, as opposed to small cell and squamous
tumors, which most often arise near the hilum. 52,53
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a tobacco history. It may be postulated that smokers, by virtue of comorbid
conditions or poorer performance status, would have a shorter survival. "Non-

smokers" may develop cancer as a consequence of environmental ("second
hand smoke") exposure, and may not have other stigmata of chronic, high

intensity cigarette use. Alternatively, It is possible that this phenomenon is not
directly linked to smoking at all. Lung cancer in non-smokers may be a distinct
pathologic entity with an inherently better clinical outcome.

Study Group

Relative risk
Cigarettes per Day

ACS-CPS
ACS-CPS
ACS-CPS

(men)
II (men)
II (women)

1-19
6.5
18.8
7.3

>20
13.7
26.9
16.3

Other risk factors

It is long past speculation that cigarette smoking is the major risk factor
for lung cancer among Americans. Although tobacco use is clearly associated
with all types of lung cancer, nonsmokers also develop these tumors. This

suggests that risk factors other than smoking may contribute to pulmonary
55
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oncogenesis. Although all risk factors have not been clearly identified, it is now
known that environmental("second-hand") exposure to cigarette smoke, radon
inhalation, asbestos, dietary deficiency in antioxidants, HIV, inactivity and certain

non-malignant lung diseases play a role’. It is of historical irony that as late as

two decades ago, cigarette smoking was considered protective against the lung

cancer sustained by uranium miners.

’

Environmental influences aside, there are several genetic factors that

have also been implicated in the development of lung cancer, including the

.

CYP1A1 and mu-1 genotypes which influence carcinogen activation and
detoxification proteins

In one case control study, individual with low levels of

the DNA repair enzyme 8-oxoguanine DNA N-glycosylase (OGG) were up to 124
times more likely to have lung cancer than those with normal levels.
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Gender Differences

Women have traditionally experienced lower rates of lung cancer than
men, a distinction that is largely related to differences in smoking prevalence.
This explanation also helps to explain the recent narrowing of the differential, as

the rate of lung cancer begins to reflect the relative increase in popularity of

cigarette use among women over the past several decades. That difference first

began to narrow in the 1960’s as the effects of increased smoking among
females emerged43.
Overall, women with lung cancer are younger than men and have smoked
less intensively. Females have a disproportionate ratio of adenocarcinoma and
small cell lung cancer relative to males. In addition, only 30-40% of females with

lung carcinoma are cigarette smokers, as compared to 80% of men. In addition
to lung cancer, cigarette smoking among women has been associated with

cancer of the bladder, cervix, esophagus, kidney, oropharynx and pancreas. 62,64
Recently there has been considerable evidence to support differences,
other than prevalence of smoking, to explain variations in lung cancer incidence
and response to therapy among women. For example, women may have
increased expression of the CYP1A1 oncogene and a lower capacity for DNA

repair. It has also been noted that estrogen signaling may have a biological role
in lung tumerogenesis. These differences, along with variations in stage at

64

Reichert, V.C. et. al. Women and Tobacco Dependence. Med. Clin. North America.
88(6).1-13. 2004.

32

diagnosis may also explain why women with lung cancer have an overall better

prognosis65,66,67

Racial and ethnic differences

There are clear differences in lung cancer incidence between ethnic and
racial groups in the U.S. These variations seem to relate both to genetic

susceptibility and differences in tobacco use.

A comparison in the incidence

among major ethnic groups in the U.S. appears in figure 6
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proven in rigorous analysis. A survey published by the Harvard School of Public
Health noted that 70% of black smokers use menthol cigarettes. This compares

to an average of 25% among all U.S. Smokers 6.

Smoking Cessation and Lung Cancer Risk Reduction

It is certain that smoking cessation is associated with a long-term
decrease in risk for the development of lung cancer43’69,z’z. This holds true for
all subpopulations, including the elderly and individuals with underlying

COPD. z’73 The relationship between smoking cessation and decreasing cancer
risk is graphed in figure 9. Attenuation of risk is least pronounced in formerly

heavy smokers. TM Details of a meta analysis on cessation-related lung cancer risk
reduction are presented in Appendix A.

Discontinuation reduces risk in all histologic types, although to various

degrees. The highest reduction is in SCLC and squamous cell carcinoma, while
69
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less risk reduction is evident for large cell cancer and adenocarcinoma, zs The
1982 Surgeon General report, The Health Consequences of Smoking cited
studies to indicate that risk reduction is time dependent and concluded, "The

more years one is off cigarettes, the greater the reduction in excess cancer risk.
Fifteen years after quitting cigarette smoking, the former smoker’s lung cancer

risk, for example is reduced close to that observed in nonsmokers", z6 This view
is far from universal, howeverTM. It is possible that smoking-mediated genetic

changes persist, independent of removal of the tobacco irritant. Cessation of
smoking would not be expected to decrease either the expression or latency of
these mutations. This would explain persistent risk in quitters, for whom the
stimulus for mutation would be removed, and would also explain some
observations of a zero-slope risk reduction over time 48.
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etc. is the problem). This notion of the incurability of cancer persisted into the
earliest 20 th century, when anecdotal reports of spontaneous remissions and

metastatic regression after surgical debulking began to accumulate.

Still, with

high surgical mortality rates in the early part of the century, the technique may

not have been useful therapy. The first modern report of pneumonectomy for

lung cancer was reported in

19334.

This milestone provided the first opportunity

for survival from a previously hopeless disease 78. Surgical resection of lung

cancer became a treatment standard in the mid 1930’s when the technique for
pulmonary Iobectomies was devised. Early surgical mortality rates were in the

range of 65%. By the end of World War II, the introduction of more limited
procedures and streptomycin had reduced the primary death rate by more than

three-quarters. It remains invaluable as primary treatment for non-small cell lung
cancer to date. z9
The therapeutic use of radiation might be as old as man himself. At
minimum, the curative effects of sunlight are documented from antiquity.

Roentgen’s discovery of X-rays in 1896 set off a flurry of research on the
therapeutic effects of ionizing radiation. Clearly, radiation had the capacity to

cause skin burns. In 1902 the development of cutaneous squamous cell cancer
after exposure to radiation was documented. An early milestone in the

development of the science of radiobiology was the discovery in 1906 that rapidly

z8
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dividing cells are more susceptible to radiation than those which are relatively

senescent. 8
The birth of chemotherapy for cancer may be traced to chemical warfare

agents of the First World War. Specifically, the ability of nitrogen mustard and its
analogues to produce leukopenia was noted during that period, even though the
mechanisms of action were not completely understood.

8

Despite the

recognition of the mustards as myelotoxic, therapy with alkylating agents was
slow to develop. A recognized highlight in the pharmacologic treatment of cancer

was the adaptation of folic acid antagonists, such as methotrexate for the
treatment of childhood leukemia. This effort was pioneered by Farber, beginning
in the period directly after World War I1. 8

1970-present

A reasonable starting point for the documentation of modern treatments for
lung cancer is 1971. By that time surgical oncology had matured, chemotherapy
was in common use both as primary and adjuvant therapy, radiation therapy had

proven its value in cancer care, and the promise of immunotherapy had begun to
blossom. That year President Richard Nixon proposed in his State of the Union
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Address, "an intensive campaign to find a cure for cancer." His commitment was
codified in December of that year with enactment of the National Cancer Act

(NCA). This legislation clearly promoted research and implementation of new
cancer treatments. At its core, the legislation provided the following

stipulationsa3:
(1) that the incidence of cancer is increasing and cancer is the disease which
is the major health concern of Americans today;

(2) that new scientific leads, if comprehensively and energetically exploited,
may significantly advance the time when more adequate preventive and
therapeutic capabilities are available to cope with cancer;

(3) that cancer is a leading cause of death in the United States;
(4) that the present state of our understanding of cancer is a consequence of
broad advances across the full scope of the biomedical sciences;

(5) that a great opportunity is offered as a result of recent advances in the
knowledge of this dread disease to conduct energetically a national

program against cancer;

(6) that in order to provide for the most effective attack on cancer it is
important to use all of the biomedical resources of the National Institutes
of Health; and

(7) that the programs of the research institutes which comprise the National
Institutes of Health have made it possible to bring into being the most

83
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productive scientific community centered upon health and disease that

the world has ever known.

(8) It is the purpose of this Act to enlarge the authorities of the National
Cancer Institute and the National Institutes of Health in order to advance
the national effort against cancer.

The legislative initiative provided $150 million for National Cancer Institute

funding of new and improved treatment regimens and was clearly a milestone in
the modern history of cancer care. 84

Peller’s review of Cancer Research, published in 1979, provides a
comprehensive view of the capabilities of lung cancer treatment in that decade

zz.

At that time surgery had become well established as primary therapy for solitary
nodules (regardless of histology) and single metastases. Of those patients

deemed operable and who accepted surgery (roughly one-third of all cases) in

two major centers, 10-25% were dead within 4 weeks. Of those who survived

surgery, however, 25% remained alive at 5 years, as compared to 1% of patients
who were ineligible or refused Iobectomy.

Chemotherapy in the 1970’s was a poor therapeutic alternative, particularly
for those patients who had sustained brain metastases. Only two agents,

cyciophosphamide and methylnitrosourea had been shown to cross the bloodbrain barrier. To maximize the odds of local and metastatic response, a

combination of 3 drugs, including methotrexate, adraimycin and vincristine, was
84
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added to the CNS regimen. This protocol was highly toxic and largely

ineffective, with a maximum improvement in survival rate of no greater than
several months.

Observing recent advances in cancer therapy requires more than tracking the
introduction of new chemotherapeutic agents. During the past 25 years, changes
in surgical oncology and radiation therapy have been profound. In addition the

formulation of complex multi-modality protocols has changed the face of therapy.

Neoadjuvent chemotherapy has provided greater opportunities for surgery or
higher dose targeted radiation.

Immunotherapy has been under development as therapy for lung cancer
since the 1970’s. BCG was the first agent recognized as a therapeutically active

immunomodulator. Morton and Pinsky and Oettgen simultaneously observed the
dramatic regression of melanoma after cutaneous injection of BCG during that

period 8. Since that time dramatic refinements, including enhanced
immunomodulation and increased tumor specificity have significantly broadened

the applications for this modality. Although immunotherapy has not had a major

impact on survival from lung cancer to date, several agents, such as BEC-2
continue to show promise and remain under investigation.

Recent changes in standard chemotherapy protocols for small cell and nonsmall cell lung cancer are outlined in tables 3 and 4. As table 1 suggests, the

key change in therapy for small cell cancer has been a migration from
cyclophosphamide-based therapy (which remains a second-line choice) to
8
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platinum-based therapy. Neoadjuvent therapy for non-small cell cancer remains
considerably less effective for inducing remissions or improving survival,

although recent data suggest a clear advantage.

The limits of treatment for

non-resectable NSCLC are evident from a recent study from Schiller and the

Eastern Cooperative Oncology Group. Among 1 155 eligible patients who were
randomized to one of four combinations of cisplatin, carboplatin, paclitaxel,

docetaxel, and gemcitabine, the response rate was only 19 percent and the two-

year survival rate was 1%8z. As data suggesting somewhat improved survival
became available, recommendations for chemotherapy-containing regimens

were endorsed for stage III, and then stage II disease. It should be noted that
significant regimen variability exists between treatment centers and that several

agents, not listed in these tables are active against SCLC, NSCLC, or both. An
extensive meta-analysis reported in 2004 demonstrated a significant

improvement in response rate and a modest 1-year survival rate increase for

multi-agent chemotherapy regimens over single-agent treatment for NSCLC,

regardless of combination. Unfortunately, additive or synergistic toxicity limits the
usefulness of combination therapy with currently available drugs. 88
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Considerable research is ongoing toward the evaluation of novel approaches

to the treatment of advanced NSCLC. Perhaps the most promising is the

development of agents directed against the epidermal growth factor receptor
tyrosine kinase. This enzyme is frequently overexpressed in common solid

tumors. Three such drugs, gefitinib, erlotinib and cetumixab (EGFR’s) are

currently available in the U.S. Phase II and III trials have recently begun to clarify
the drugs’ treatment potential. They appear to improve disease-related

symptoms and induce radiographic tumor regression, but have not clearly been
shown to prolong survival. Clearly, survival data will change as duration of

experience with this class of drugs increases. 9,90,9,. A closer analysis

demonstrates heterogeneity of response. Roughly one in ten NSCLC patients
treated with epidermal growth factor inhibitive therapy show dramatic response
and possible long-term benefit. 9’93’94
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1979

Procarbazine plus5-fluorouracil

1982 Cisplatin plus
cyclophosphamide, doxorubicin, vindesine

1990

Cisplatin, cyclophosphamide and doxorubucin or
Cisplatin and vindesine

1992 Cisplatin, cyclophosphamide and doxorubucin

with or without

etoposide

1997

Cisplatin and mitomycin with or without
ifosfamide

2004

Cisplatin/Carboplatin plus etoposide for extensive
disease add irinotecan. Consider gefitimib.

Table 3. Conventional chemotherapy for small cell lung cancer in 1979
1992zl, 199767 and 200472

1979

,

1982

u, 1990

Vincristine plus doxarubicin plus cyclophosphamide

1982 Cyclophosphamide plus at least two of the following:
vincristine, doxarubicin, CCNU, procarbazine, etopaside,
vindesine or hexamethylmelamine.

1990

Vincristine plus doxarubicin plus cyclophosphamide or
Cisplatin plus etoposide

1992 Vincristine plus doxarubicin plus cyclophosphamide, with or
without Cisplatin or etoposide

1997 Vincristine plus doxarubicin plus cyclophosphamide, with or
without Cisplatin or etoposide

2004 Cisplatin/Carboplatin plus etoposide for extensive disease add
irinotecan

Table 4. Conventional neoadjuvent chemotherapy for non-small cell lung cancer in
O0
19829-6 ,199097 ,199298 ,199799 and 2004

197995,
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Dorr, R.T. and Fritz, W.L. Cancer Chemotherapy Handbook. Elsivier Publishing,
New York. 1980 pp.65-66.
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Cancer: A Manual for Practitioners. American Cancer Society Massachusetts Division.
1982. pp 158-168.
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Smoking Cessation
Each year, 40% of all American smokers attempt to quit. At any given
time, approximately half of those are ready to take

action. Of those 20 million,

however, only about 6% succeed over the long term.

The percentage of those

who succeed has much to do with commitment to the effort, duration of smoking,
number of cigarettes, genetic predisposition toward dependent behavior, and

supportive therapy. Among smokers with insurance coverage for comprehensive

smoking cessation therapy who wish to quit, only about half take advantage of
their insurance benefits. The other half attempt to quit without

assistanceS3.

Variables statistically associated with higher and lower abstinence rates include

the followingS4:
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Skeel, T.T. (ed.) Handbook of Cancer Chemotherapy. Little Brown and Company,
Boston. 1991. pp158-166.

98

Rubin, P. Clinical Oncolo.qy: A Multidisciplinary Approach for Physicians and Students.
7th edition. W.B. Saunders Company, Philadelphia. 1993. pp. 645-666.

99

Felip, E. and Rosell, R. Neoadjuvent Chemotherapy in Non-small Cell Lung Cancer.
Current Medicinal Chemistry. 9(8);893-898. 2002.
loo

Clinical Practice Guidelines in Oncology. National Comprehensive Cancer Network.
2004.

www.nccn.orq.
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Prochaska, J.O., and DiClemente, C.C. Stages and Processes of Self-change of
Smoking: Toward an integrative model of change. J. Consult Clin Psychol 51;390-395.
1983.
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Smoking Cessation During Previous Year Among Adults-United States 1990 and
1991. MMWR 42; 504-507. 1993.

103

Curry, S.J. et. al. Use and Cost Effectiveness of Smoking-cessation Services Under
Four Insurance Plans in a Health Maintenance Organization. NEJM. 339(10) 673-679.
1998.
104

Treating Tobacco Use and Dependence. U.S. Department of Health and Human
Services. 55. June, 2000.
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High abstinence rates

Low abstinence rates

High motivation

High nicotine dependence

Ready to change

Previous failed attempts

High self-confidence

Psychiatric comorbidity

Supportive social network

High stress level

This overall rate has remained relatively constant, although the addition of

behavioral therapies, nicotine replacement products, acupuncture, hypnosis,

anxiolytics, and antidepressants has had a dramatic impact in the cohort of
smokers using them. A comparison of meta-analyses for various medications is
in figure 10. Studies have now demonstrated 22%-38% long-term (>6 months)
abstinence rates with combined therapy.

It is reasonable to anticipate that a

program utilizing combined therapy, including counseling, nicotine replacement
and bupropion or tricyclic antidepressants will have a long-term success rate of

about 25% among smokers who are motivated to quit. Data showing the

success rates for entire populations of smokers (including those who are coerced
into enrolling into cessation programs) are not available.
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Jorenby, D. et. al. A Controlled Trial of Sustained Release Bupropion, a Nicotine
Patch, or Both for Smoking Cessation. NEJM 340(9); 685-691. 1999.
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comprehensive analysis of these costs. The study group evaluated the effect of

smoking history on the presence of smoking-related medical conditions (heart
disease, emphysema, arteriosclerosis, stroke, and cancer), calculated

probabilities and applied that data to the cumulative cost of treatment. Hospital

expenses, physician fees, pharmacy expenses, home health care and nursing
home charges were summed to reach the total smoking attributable cost.

In

1987 alone those charges added to $21.9 billion. z By 1998 that total had
increased to $75.5 billion. 8

The breakdown of these expenses is diagrammed

in figure 12. This estimate was confirmed in published data, where the smoking-

attributable fraction of healthcare cost was calculated to be somewhere between

4-7%9.

The incremental increase occurred despite a declining prevalence of

cigarette smoking in this country, and likely reflects both the increase in cost-per-

.

service and the latency of smoking-related illness. Almost half of Medicare’s

drug budget of $10.5 billion went for cancer drugs in 2003

*Asymptomatic brain metastases, common in small cell lung cancer, were virtually
impossible to diagnose in the pre-CT era. Thus dissemination to the central nervous
system was a more frequent and severe complication.
Medical-care expenditures attributable to Cigarette Smoking-United States, 1993.

MMWR 43(26). 1994 469-472.
o8

Smoking-Attributable Expenditures 1998. CDC National Center for Chronic Disease

Prevention and Health Promotion.

http..//apps.nccd.cdc.gove/sammec/show same data.asp
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Miller, V.P., Ernst, C, and Collin, F. Smoking-attributable Medical Care Costs in the
USA. Soc. Sci. Med. 48;375-391. 1999.

0

Harris, G. Proposal Would Cut What Medicare Pays for Cancer Drugs. The New
York Times. July27,2004. C1.
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Unfortunately, there are also program cost savings associated with
smoking that somewhat offset the incremental increase in healthcare
expenditures. Frank A. Sloan, director of the Center for Health Policy, Law and

Management at Duke University calculated that the decreased life expectancy
associated with cigarette smoking resulted in Social Security savings of $1,519

for a 24 year-old female smoker and $6,549 per 24 year-old male.

Also to be

considered are savings in Medicaid payments for custodial care and government
administered payments for the non-smoking-related illnesses of the elderly.

The cost of medical care in the United States is clearly linked to coverage
and reimbursement of private insurers. This model has seen dramatic change
with the proliferation of managed care in the 1990’s. The burden of lung cancer

on insurance carriers has been studied in the context of this paradigm shift. A
benchmark was established in 1998 based on the analysis of Hillner’s group. His

study estimated that the cost of care for patients with non-small-cell lung cancer,
who survived less than one year was $47,280.

Despite an intuitive conclusion

that smoking is associated with increased health care costs, the Kaiser
Foundation found no difference in a tightly controlled managed care environment.

Although smokers experienced a higher rate of hospitalization, this increase in
utilization was offset by a lower frequency of outpatient service utilization. The

suggested explanation for this phenomenon was that smokers have a lower
111

Smith, H. The High Cost of Smoking. MSN Money.
http://moneycentral, msn.com/content/I nsu rance/I nsu reyou rhealth/P 100291 .asp
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Hillner, B.E. et. al. Costs of Care Associated with Non-Small-Cell Lung Cancer in a
Commercially Insured Cohort. J. Clin. Oncology. 16(4);1420-1424. 1998.
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Some analysts have proposed that lung cancer is a relatively inexpensive
disease to treat. They argue that bronchogenic carcinoma is a quick and efficient

killer, which spares society the burden of paying for more insidious diseases
such as chronic heart failure, and senility ’6. This theory ignores several key
points:

Lung cancer risk reduction strategies do not exist in a vacuum. In
parallel with this effort are advances in risk reduction for a wide variety
of illnesses.

Morbidity and mortality costs associated with lung cancer do not
reflect the cost burden of lost productivity, especially in pre-retirement

years.
Smoking cessation will reduce the expense associated with other

pulmonary and cardiac diseases such as emphysema and myocardial
infarction 7.

Reduced passive exposure to cigarette smoke can decrease the
burden of disease among non-smokers. Roughly half of the smoke

generated by cigarette combustion enters a local environment as
sidestream smoke. The associated effects are similar to those of

smokers and include low birth weight (due to exposure during
11s

Sturm, R. The Effects of Obesity, Smoking, and Drinking on Medical Problems and
Costs. Health Affairs. 21 (2):245-253. 2002.
116

Leu, R.Eo and Schaub, T. Does Smoking Increase Medical Care Expenditures? Soc.

Sci. Med. 17; 1907-14. 1983.
z

Ibid Surgeon General’s 1990

Report on the Health Benfeits of Smoking Cessation...

below.
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pregnancy), sudden infant death syndrome, acute lower respiratory
tract infections, asthma, middle ear infections, and chronic respiratory

symptoms in children, lung cancer, nasal sinus cancer, and coronary
heart disease. 118

As the cost of patient care for smoking-related disease increases it is
reasonable to ask several questions:
1. Have advances in patient care for smoking-related cancer result in

improved survival?
2. How does medical inflation impact on the cost of care

3. In addition to lung cancer expenses, are medical costs increased in
smokers for comorbid smoking-related illnesses as well?
4. Might additional resources and emphasis on primary prevention (through
avoidance and cessation programs) result in a net healthcare savings by

reducing the burden of lung cancer?

This thesis will examine these questions as reflected by the effectiveness

and cost of treatment for primary carcinoma of the lung and airways. It will graph

the survival from these diseases over the past thirty years and look at recent

trends in cost-for-treatment. It is anticipated that these analyses will facilitate
decisions concerning resource allocation and the emphasis of primary prevention

Environmental Tobacco Smoke. National Cancer Institute Cancer Facts. 2000.

http://cis.nci.nih.qov/fact/10 18.htm.
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relative to acute and chronic care.

Calculating the Cost of Smoking Cessation
This introduction has documented the relationship between cigarette

smoking and lung cancer as well as the association between smoking cessation
and decreased cancer risk. Clearly, quitting cigarette use saves lives. It is
intuitive that broad application of cessation would decrease smoking-related lung

cancer costs and result in an associated health care savings. Although there is a
large body of evidence in its favor, this theory has not been unequivocally
established. Wagner, et. al., for example, showed a relative net increase in

hospital costs for ex-smokers during the first year after cessation, followed by

progressive decreases in healthcare utilization for the next 5 years 9. The
"break even" point of utilization occurred during year 4. Other authors have
replicated this data.

It was concluded that the increase in early cost was due

to underlying acute or progressive disease that often was the motivating force for
individuals to discontinue cigarettes ’1.

1

Wagner, E.H. et. al The Impact of Smoking and Quitting on Health Care Use. Arch Int
Med. 155. 1789-1795. 1995.
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Warner, K.E. The Costs of Benefits: Smoking Cessation and Health Care
Expenditures. American J. Health Promotion. 18(2): 123-124. 2003

121

Martinson, B.C., O’Connor, P.J., Pronk, N.P., and Rolnick, S.J. Smoking Cessation
Attempts in Relation to Prior Health Care Charges: The Effect of Antecedent Smokingrelated Symptoms? American J. Health Promotion 18(2) 125-132. 2003.
1

Munisch, S.et. al Pattern of Medical Charges After Quitting Smoking Among Those
with and Without Arthritis, Allergies, or Back Pain. American J. Health Promotion 18(2)

133-142. 2003.
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The net healthcare savings (or cost) of smoking cessation is a function of

numerous variables, which may be categorized as follows:
Primary costs associated with smoking cessation (paid through public health,
private insurance, NGO-sponsored programs or individuals) 23

Cost of clinicians screening the U.S. population
Cost of advertising and promoting smoking cessation
Cost of medical care for counseling and medication therapy
Motivating unwilling smokers to try and quit
Direct intervention costs including educational materials, counseling,
medications and alternative therapies

Secondary costs associated with smoking cessation
Inevitable cost of diagnosis and treatment of non-smoking related illness

Healthcare costs associated with increased longevity, such as those
associated with custodial care

Healthcare savings from smoking cessation

Reduced number of screening procedures for smoking-related disease

Fewer diagnostic tests for evaluation of smoking-related disease
Less treatment for smoking-related disease, including surgery, medical
therapy, and radiation therapy

Lower therapeutic (other than smoking cessation) pharmacy costs
123

Cromwell, J, et al. Cost-effectiveness of the Clinical Practice Recommendations in
the AHCPR Guideline for Smoking Cessation. JAMA 278(21);1759-1766. 1997.
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Reduced rehabilitation costs

Reduced medical expenses from individuals exposed to second hand
smoke

This project will scrutinize the current approach to lung cancer in America as

measured by the effectiveness of treatment and relative cost-effectiveness of

prevention. The former will be determined by analysis of recent trends in lung

cancer survival. Cost effectiveness has been defined by Doubilet as a given
intervention that (i) achieves a given quantified objective at a lower cost than all

alternative interventions intended to achieve the same objective or (ii) achieves

more of the desired objective than do the alternatives when identical levels of

resources are devoted to each intervention4.

Other applications of the term

include the criterion of having an additional benefit worth the additional cost.

Thus, cost-effectiveness will be calculated as the differential between the cost of

lung cancer treatment and the net cost of primary prevention through smoking
cessation programs. Evaluation of these parameters will allow for restatement of

the current balance between prevention and patient care efforts in lung cancer

care. Recommendations for social policy realignment will follow.
Achieving these goals will require consideration of four questions, which may
be stated as follows:

124

Warner, K.E. Cost Effectiveness of Smoking-Cessation Therapies.
Pharmacoeconomics. 11(6); 538-549. 1997.
Doubilet, P., Weinstein, M.C., and McNeil, B.J. Use and Misue of the Term "Cost
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1. Despite numerous important advances in the treatment of lung cancer,

have the One, three, five, and ten-year survival rates improved?
2. What is the cost of treating lung

cancer?

3. What is the real cost of a comprehensive smoking cessation program?
4. Is primary prevention through smoking cessation effective and efficient
relative to treatment for lung cancer?

The findings of this study will be based on available statistical records and a
cohort analysis of Americans diagnosed with lung cancer. Per capita medical

costs, hospital admissions/100 cases, total annual hospital days/100 cases,

ambulatory visits and cancer-related cost will be compared with a peer group of
individuals who have not been treated for this disease.
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Section II Methods
-As an example to others, and not that care for moderation myself, it has always been my
rule never to smoke when asleep and never to refrain when awake.-Mark Twain on his Z
birthday

Survival from lung cancer

Historical data on lung cancer survivability will be gleaned from CDC-

.

SEER tables and other sources available by Med Line, MD Consult,
FIRSTConsult and manual literature reviews

Data will be presented

graphically, so as to best display improved survival (or lack thereof) over time
and a therapeutic plateau, if one exists.

Cost-effectiveness of primary prevention relative to patient care for lung cancer

The methods described below will compare the cost of lung cancer care
for beneficiaries that smoke but do not access enhanced smoking cessation

therapy to the cost of care plus the cost of a program providing comprehensive
smoking cessation therapy for beneficiaries who choose to enroll. It will utilize
data from the U.S. workforce and adult beneficiaries of a single large
multinational corporation. Total cost of the cessation benefit group is the sum of

1) treatment cost for continuing smokers who develop cancer, plus 2) the cost of
care for quitters who develop cancer, plus 3) the cost of smoking cessation

therapy. Determination of diagnosis will be based on insurance billing records
accrued in the MedStat database for the employer (>200,000 U.S. adult

beneficiaries) for the years 2001-2004. Included are all inpatient claims,
National Cancer Institute Surveillance, Epidemiology and End Results.

ttp://seer.cancer.qov
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outpatient claims ancillary service claims (such as physical therapy and
nutritional counseling) and inpatient pharmacy costs. The cost of mental health

care, outpatient pharmacy and dental services is not included. To minimize age
bias, only records of individuals between 40-65 years of age will be included.

Groups will be compared for the frequency of diabetes (types and II),
hypertension and coronary artery disease (all diagnoses, including angina and
myocardial infarction), three significant comorbidities Cost data will be

presented for all cancers of the trachea, lung and bronchus, which have been

grouped and coded among the CDC designated smoking-related cancer

group 127:
ICD 162: Malignant primary neoplasm of trachea, bronchus and lung
ICD 231.2 Cancer in situ of bronchus and lung
ICD 235.7 Neoplasm of uncertain behavior in trachea, bronchus, lung
Medstat has created the database from claims data submitted by multiple

company insurers, and provided the basic tabular form used in this report.
Absent from this compilation are employees who use non-company benefits

(such as those provided by a spouse’s employer), non-U.S, employees,
contractors, and other individuals not receiving medical services as a core

company benefit.

127

International Classification of Disease Codes. CDC.
http://apps...., nccd.cdc..qove/sammec/icd codes.asp

*Calculated as the cost of medical care (which includes the cost of inpatient and office
pharmacy) + the cost of outpatient pharmacy
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Individuals who are billed for a diagnosis of lung cancer on consecutive

(or non-consecutive) years are included separately for each year.
Cost of care will be calculated as the sum of the cost of inpatient and
outpatient medical services. Chemotherapy and inpatient pharmacy costs will be
considered in the calculations, while outpatient pharmacy costs will not.

The relative cost of smoking and smoking cessation will be calculated as
follows:
1. The Cost of Care for Lung Cancer:
This model calculates this cost by estimating the risk of cancer among

smokers, the cost of yearly care as determined by Medstat statistics, the cost of

care for those smokers who do not develop bronchogenic carcinoma, and the

average longevity of patients with lung cancer. The formula may be written as
follows:
where

S=Number of individuals in the smoking cohort (persons)

P=Ten year probability of lung cancer among the cohort of smokers
C=Average differential in cost of care for beneficiaries with lung cancer per year,
including outpatient care, inpatient care and pharmacy costs. (Dollars/year)

L=Average longevity of a lung cancer patient in the cohort (Years)
Prevalence variations for comorbid diseases such as coronary heart
disease, diabetes, and hypertension may suggest that lung cancer patients have
increased risk for other smoking and non-smoking-related chronic diseases. For

that reason and because some of the cost of care for lung cancer may be
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obscured because of billing under a comorbid diagnosis, this study uses total
cost of care used by lung cancer patients for financial analysis, rather than cost

of lung cancer treatment alone.

2. The Cost of Smoking Cessation Benefits

The cost of smoking cessation may be calculated as the medical care

cost of lung cancer patients who had succeeded in long-term cessation, plus the

care cost for those who attempted, but were unsuccessful, plus the medical cost
for individuals who did not attempt to quit despite the availability of cessation
benefits, plus the cost of smoking cessation programs. This concept is

represented graphically as figure 13 and may be disassembled to the following
equations:

R=The fraction of smokers that will attempt to quit. The value for R was been

documented earlier in this report and is in the range of 40%3.
Q=Overall quit rate

among smokers entering comprehensive cessation

programs. A discussion of this value follows below.

P=Ten year probability of lung cancer among the U.S. population of "typical"
former smokers
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that the lung cancer risk and treatment outcome (longevity) among active and

former smokers in this population is identical to those of the American public as a
whole. In terms of smoking cessation, these calculations are based on the
anticipation that the utilization, efficacy and cost of a multi-modality cessation

program is the same for both this population and those of referenced studies.

Lung cancer risk (P)
To calculate a reasonable expectation for the risk of lung cancer among
smokers, a ’typical" cigarette user profile needs to be established. For the

purposes of this thesis, such an individual is 50 years of age, male, has not
experienced asbestos exposure and has smoked one pack of cigarettes per day
since age 15.

According to the Memorial Sloan-Kettering model, 3% of these

people develop some form of respiratory cancer within 10 years.

Longevity after diagnosis of lung cancer (L)

Obviously longevity is dependent on numerous factors including stage at
diagnosis, histology, comorbid conditions, performance status, and even access
to healthcare services. Curves have been generated based on staging, one of
which is presented as figure 14. To calculate an average period during which

care (and expense) for lung cancer needs to be provided this study assumes an

equal distribution of patients at each pathologic stage. By this calculation, a
"typical" lung cancer patient survives for an average of 30.25 months (2.52 years)
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Figure 14 Kaplan-Meier survival curves of lung cancer survival by stage, incorporating all causes of
mortality 128

Smoking cessation success rate (Q )

For the purpose of these calculations a cessation success rate of 0.25 will
be used. This value considers the published data and is a reasonable
approximation of what might be anticipated from the combination of intervention
with practitioner enrollment, nicotine replacement, bupropion therapy and
behavior

modification3-.

Incorrigibility
Previously cited studies estimated that each year 40% of smokers in the

U.S. attempt to quit. Despite all types of motivation and strategies, the majority
fails to stop using cigarettes in any given year. This thesis assumes that the

treatment failures rejoin the general pool of smokers for the purposes of
estimating number or quitters, for the succeeding three years. Those individuals
28

Reed, M.F. Survival After Resection for Lung Cancer Is the Outcome That Matters.
Am. J. Surgery. 188(5). 598-602. 2004.
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The rate of risk reduction after smoking cessation (P)
The Sloan Kettering model notes a 67% reduction in 10-year lung cancer
risk among ex-smokers. This figure reflects average risk reduction during that

period, from effectively zero at the moment after the last cigarette is

extinguished, to greater than two-thirds for ex-smokers who remain cancer-free
for the next decade. Given the estimation of a 3% 10-year risk for "typical" active

smokers, the average 10-year lung cancer risk of 1% will be used as an average
for the cohort of former smokers.

Re-use of smoking cessation benefits
No data was found to show the rate of re-enrollment of failed smoking
therapy patients into programs in succeeding years. This study will assume that
individuals who fail cessation therapy re-enter the general cohort of smokers and

are as likely as the therapy na’ve group to utilize smoking cessation benefits in
the succeeding three years. After three years, these individuals, as incorrigibles,

would not further re-use these benefits at any significant rate.

Fraction of attempting quitters using available services (B )

At least one previously cited study has shown that only half those offered
comprehensive therapy will take advantage of the service. Those who do utilize
the benefit have a far superior quit rate than those attempting self-cessation.
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Cost of an average smoking cessation program (A )
There are myriad permutations of treatments for nicotine dependence.
Their cost ranges from trivial ("learn to quit" literature) to very expensive

(combined modalities). As demonstrated above, there is reasonable correlation
between the type of therapy and success rate. The calculations in this report are

based on the provision of a highly effective, multimodality program. The charges
used in this calculation, therefore, reflect 2005 expenses for practitioner
intervention, nicotine replacement, bupropion therapy and Internet-based
behavioral therapy. The cost for each of these interventions is based on typical

charges or average wholesale prices for medication. Not entered into this
calculation is the cost of advertising and promotion of smoking cessation

programs. This expense will be considered in the discussion section, however.

Statistical relationship between smoking and lung cancer

The calculations in this paper rely on data demonstrating that the

overwhelming majority (90%) of Americans with lung cancer are smokers44. Also
to be considered in the real world are those who develop lung cancer as a result
of sidestream or mainstream environmental cigarette smoke ("second hand

smoke"). Individuals who develop lung cancer as a result of environmental
tobacco smoke are not factored into the cost of care calculations, and are not
considered in the potential impact of smoking cessation. Clearly the relationship

between quitting cigarettes and risk reduction is different between smokers and
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those exposed to exhaled smoke. This distinction, however, is considered to be

non-significant for the purposes of this thesis.

Baseline medical costs

These formulas assume that the per-member-per-month (PMPM) medical

expenses accrued by all individuals who do not develop lung cancer are
equivalent and that this baseline applies to those with cancer as well. The
assumption allows the incremental cancer expense to be calculated as the

PMPM for the cancer group minus the PMPM for the non-cancer cohort.

Adjustments for inflation

These statistics assume that the patterns of inflation for general care and

care for individuals with lung cancer continue to follow the same slope of the

years referenced in the study. The raw data suggest zero inflation for the cancer
group and a 27.4% average (non-compounded) increase in general medical
expenses for the entire 4-year period (6.8% per year). The cost differential over
a 10-year follow-up period, baseline medical expenses will reflect an averaged
adjustment of 34% above the 2004 baseline PMPM. It should be noted that this

rate is significantly lower than the national medical inflation average for the

period studied and may not be reflective of future increases.
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Pharmacy costs

Chemotherapy costs, which may be substantial, are captured within the
cost of inpatient and outpatient services. Although several types of drugs (such

as analgesics) are frequently used by cancer patients, it is reasonable to
anticipate that relative outpatient pharmacy costs will not be significantly impact
the relative cost of care for the treatment of lung cancer.
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Section III Results
...as the search (for a cancer cure) moved on toward final solution, beams of light are
focused on enlightening discoveries which save more and more lives, and now if everyone
would only take advantage of all knowledge and treatment available, one in two could be
cured-"The Search Goes On" Publication of the New York chapter of the American Cancer
Society. 1975

Demographics

As demonstrated in table 5 the age and gender distribution is different for
the cohorts under study for this thesis. The average age for a lung cancer

patient is 57.15 years, while individuals without lung cancer (within the age 40-65

parameter for the study) average 51.78 years. The lung cancer group is 46%
male, while the unaffected cohort is 49% male. These differences are
statistically significant, but are unlikely to measurably affect the cost of care..

Lung Cancer
Ages 40 65
3 Years Incurred Data
4Q01

3Q04

Average Age
p value
Cancer
Patients
Lung
male
female
% male

Control Group
male
female
% male

2OO4
2002 | 2003
2001
0.0002
<.0001
0.0022
0.0041
57.2
57.0
57.3
57.1
57.1
57.3
57.3
57.5
57.2
56.8
57.3
56.8
48%
44%
46%
46%
51.6
51.7
51.6
49%

51.7
51.7
51.7
49%

51.8
51.9
51.8
49%

52.0
52.0
51.9
49%

Table 5 Demographic Comparison of Cohorts
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Survival Rates

There has certainly been improvement in survival from lung cancer over
the past half-century. In the period from 1950-1954 the relative 5-year survival

rate for all cases was 6%, compared to the 1992-1996 rate of 15.1%. It is
reasonable to conclude that treatment advances improved survival during that
interval. Hidden in those statistics, however, is lead time bias related to

improved imaging (primarily CT and MRI) and invasive diagnostic procedures

(such as via thoracoscopy and image guided needle biopsies). Also inevident is
the effect of increasingly sophisticated treatment for comorbid conditions and

non-smoking-related illness.

In 1950 the average life expectancy (male and

female combined) in the U.S. was 68.07 years. That average increased to 76.9

years in 2000 and 77.6 years by 2003. 9’3 More accurate, and of greater
relevance for this discussion, is a review of survival data for the period between

enactment of the National Cancer Act in 1971 and today. Data for the past

quarter-century has been collated by the National Cancer Institute into the SEER
database. Progression of cancer survival is graphed in figure 16.

129

Simao, Paul. Life Expectancy in U.S. Hits Record High. Reuters. News. March 1,
2005
30

Life Expectancy. National Center for Health Statistics.
www.cdc.qov/nchs/faststats/lifexpec.htm.
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the survival advantage for the surgery-plus-chemotherapy group was only 5%

greater than that for patients treated with surgery alone

3

The Cost of Lung Cancer Treatment

The cost of medical care for the employee population studied is

presented in table 6. Not evident from the table is the reality that lung cancer
treatment costs in the U.S. reflect wide practice variations. Although these
differences often are reflected in variations in outcome, such is not always the

case. 33 The data presented in this table suggest that the PMPM cost of medical
care for lung cancer patients is between $2,990-$3,713. The average PMPM
during the study interval was $3,261. The net PMPM (lung cancer medical cost
minus baseline medical cost, adjusted for inflation) is $2,823 or $33,876/year.
This value will be used

(as "C"-the average cost of care for individuals with lung

cancer per year) in the calculations to follow. Of note is the complete lack of
inflationary pressure on the cost of care for patients with lung cancer. Although

an in-depth analysis of the cause of this phenomenon is outside the scope of this
thesis, two possible cost savings mechanisms are evident from the available

data:
1. Decreased rate of hospitalization
2. Shorter average hospital length of stay
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Both of these phenomena suggest that the increasing use of outpatient services
is helping to control the cost of care. It cannot be determined whether these

efficiencies can continue to stabilize overall expenses. If not, the cost of care

should rise in step with general medical inflation, further magnifying any

advantage of primary prevention.

As might be expected, the prevalence of comorbid conditions is
substantially higher in the cohort of employees with lung cancer than the control

group. This relationship is greatest with individuals with coronary artery disease,
which would be expected, given the association between both atherosclerosis

and lung cancer among smokers. Although there is no direct link between

smoking and diabetes or hypertension, it may be postulated that the same social

forces and personality patterns that induce smoking also contribute to obesity
and excess sodium consumption, risk factors for those illnesses.
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2005 dollars). This estimate adds the cost of physician or nurse enrollment and

pre-treatment counseling. 103,123

A contemporary estimate of the cost of smoking cessation considers the
cost of practitioner services (enrollment into a comprehensive treatment program,
prescriptions and oversight of prescription therapy), Internet-based counseling

(such as QuitNet), the cost of a seven-week course of bupropion, and nicotine
replacement. The cost may be estimated as follows 134:
Practitioners services-2 office visits @$50/visit

$100.00

30 days therapy with transdermal nicotine replacement

102.00

7 weeks therapy with bupropion (Zyban)

115.00

Enrollment fee for QuitNet (lifetime membership)
Total cost per enrollee

99.95
$416.95

Using the use of average wholesale prices for bupropion, this value is in
line with those of the studies cited and will be used as (A)for the calculations to

follow.
The total number of individuals using (and re-using) smoking benefits is

based on the utilization rates graphed in figure 17. Over a three-year period,

24,206 smoking cessation packages will be used. Some smokers will use the

package on up to three attempts. Derivation of this total is displayed in figure

134
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intervention is provided. Thus, the number of "net smokers" is 42,953

(calculation demonstrated in figure 15, above).
2. Cost of care in the absence of a smoking cessation program:

Of the 46,200 smokers, 40% will attempt to quit each year for the first

three years (after which they are presumed to be incorrigible). In the
absence of a cessation benefit, the expected cessation rate is 6%.

Thus, after the first three years, 42,953 smokers will remain.

Treatment costs-3% O-year risk x 42,953 smokers x
$33,876/case/year x 2.52 years=S/10,003,734 over 10 years

3. Cost of a comprehensive smoking cessation program

24,206 program enrollees x $416.95/enrollee=$10,092,692 over 10

years
4. Savings from cancer avoidance

150 cases avoided X $33,876/case/year X 2.52 years=S12,805,128

over 10 years

Overall savings =$12,804,128- $10,092,692 = $2,712,436
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Section IV Discussion
-Over the last century we have extended life expectancy by 30 years, but that only
8 of those years can be credited to medical intervention.-Hillary Rodham Clinton,
2004 3

The Value of a Dollar of Prevention
This study has demonstrated that each dollar of primary prevention

through a comprehensive cessation program yields only a small direct savings
over simply caring for smokers who develop lung cancer. This difference is
unlikely to be significant in the context of unmeasured expenses and savings.

Although the calculations demonstrate no significant difference, this should be
viewed as only one savings stream among a variety of smoking-related illnesses

and costs. Not considered is the cost of caring for other smoking-related
illnesses such as emphysema and coronary artery disease. It excludes likely

indirect savings on disability costs, the expense associated with exposure to

second-hand tobacco smoke, and lost productivity related to smoking-related
disease. Although not calculated for this thesis, those savings would likely
increase the total by a magnitude of

5.0-6.0136’137. It is most critical for the reader

not to lose sight of the greatest savings demonstrated in this study. A
comprehensive, fully funded smoking cessation program can prevent

roughly 350 cases of a horrible and essentially incurable disease per
135
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100,000 smokers, over a lO-year period. Thus, it should be concluded that
aggressive smoking cessation strategies could be financially sound and are

definitely in the interest of the public’s health.

Treatment for Lung Cancer-Why Isn’t Survival Improving?
It would be incorrect to deny the extraordinary advances that have
occurred in the fields of oncology since the advent of modern medicine and

especially within the last quarter century. Certain neoplasms such as gestational
choriocarcinoma, childhood acute lymphoblastic leukemia and Hodgekin’s

lymphoma may be cured with currently available chemotherapy. Improvements
in treatment of cancers of old age, such as carcinoma of the prostate have

prolonged survival past the average life expectancy for many with these
diseases. It is clear, however, that advances for lung cancer have not been

nearly as successful.
Analysis of year-to-year variations (or lack thereof) in survival from lung
cancer is more complex than the data might suggest on first pass. Numerous
confounders and significant bias create the potential for misinterpretation of this
crude data in both directions. These include the following:

Stage at diagnosis-SEER data on lung cancer does not stratify survival
based on presenting stage. Thus advances in early detection may
influence outcomes.

Histology-Unquestionably, tumor histology has bearing on response to

treatment, especially between small cell tumors and non small-cell
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varieties. It was documented earlier in this thesis that the relative mix of

these histologies has, in fact, changed over recent decades. The raw
data presented in the SEER table does not permit identification of trends
within histologic categories, and certainly provides no insight into

treatment success among subcellular subtypes.
Lead time bias-Not only will early detection improve overall survival rates,
patients who are identified earlier in the course of their disease enter the
survival databank before those for whom the diagnosis is delayed. This

likely contributed in part to the improvement trend that was noted.

Comorbidity-Several aspects of comorbidity and the treatment of
coexistant illness may impact on survival data. The crude statistics cited

on the SEER database are not age adjusted and not adjusted for such
confounders as non-cancer related disease (such as emphysema or

coronary disease) that might limit the potential for surgical resection or
the tolerability of chemotherapy. Non-smoking related illness, more

prevalent in the aging population, is also not considered.
Despite the recognition that bias and confounding inherent in SEER data may
alter the statistics, it still remains clear that the slope of survival over the past

quarter century has been extremely flat. The probability of surviving for 5 years

clearly plateaued before 1975 and remains constant, at least in practical terms.

Lung cancer, and especially locally invasive or metastatic cancer remains a killer.
There are common difficulties to the development of effective therapy for all

malignancies. They include the following:
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Developing strategies that specifically or preferentially target tumors

Clearly cancer therapy is limited by toxicity to normal tissues and adverse
reactions. Novel treatments are needed that either are tumor specific or are

bound to tumor specific delivery agents. Although not yet clearly evident in

mortality data, emerging chemotherapeutic advances are being designed for
tumor specificity. One such formulation, Abraxane, encapsulates the

chemotherapy agent paclitaxei with albumin, a transport protein that can carry
the drug directly to cancer ceils 3s. Similarly, advances in endoscopic therapy,

microsurgery, cryotherapy and brachytherapy have advanced treatment

effectiveness, although these modalities remain largely palliative.

Completely

novel approaches, including gene therapy offer significant theoretical promise as

Bypassing physical and biological separations, such as the blood-brain barrier

SCLC, in particular has a propensity for early metastasis, especially to the
central nervous system. This and other safe harbors complicate the total
eradication of tumor by chemotherapy. There have been significant advances in

understanding the various processes that "protect" the CNS from foreign

substances, including mechanisms specific to tumors. Clearly tumor interactions
with microglia and various matrix proteins, cytokines and growth factors have a

138
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central role 139. In parallel with these insights have been the development of

strategies to bypass the barrier and effectively limit the potential and effect of
brain metastases. These include prophylactic intracranial irradiation, and

conjugation of neuroactive medications with peptidomimetic

ligands140’141.

Limitations of current preclinical modeling

Advanced preclinical research typically involves observing the behavior of
specific tumors in animals, most often mice. There are significant shortcomings
in this approach that diminish research yield. For example, the genetic similarity

between mice and men does not uniformly translate into similarities in natural

history of disease or response to therapy. Animal research also assumes that a

cancer line is genetically static, when in fact continuing mutations impact the
clinical effectiveness of most therapies 84.

Tumor heterogeneity

Most if not all cancer types are, in fact, a highly heterogeneous series of
relatively distinct diseases, which share a predilection for genesis in a specific

organ. Thus, one would not expect a single treatment breakthrough to be
uniformly effective. Lung cancer is no exception. Beyond the histologic
139
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characteristics of SCLC and NSCLC are myriad subcellular variations. It has

now been determined that susceptibility to at least some forms of therapy

depends on tumor genes and their expression. Implications of the emergence of
genomics in clinical care are discussed below. 9’4

That some patients with advanced lung cancer will have a dramatic or

prolonged response to therapy is a critical point that should not be overlooked.
Each year, for example, 140,000 patients with NSCLC are identified in the United

States alone. If only 10% respond to advanced therapy such as gefitinib, the
benefit in life-years and DALY’s is enormous 93.

Why Smoking Cessation Was Not Cost Effective in this Analysis

In this study "an ounce of prevention" did not lead to "a pound of cure".
However counterintuitive, it should not be surprising that a comprehensive
smoking cessation does not lead to more substantial reductions in lung cancer

cases and net savings in lung cancer treatment. This study provides insight into
counterbalance between lung cancer treatment savings and cessation costs.
These include the following:

1. Lung cancer is an efficient killer-By and large, bronchogenic carcinoma

should not be considered a chronic disease. Unlike diabetes or coronary

insufficiency, lung cancer is not, on average, compatible with prolonged
142
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survival. Though expensive to treat on a monthly basis, these costs do

not accrue over many years.
2. Contemporary cessation programs still lack general effectiveness-Though

a marked improvement over single modality therapy and "cold turkey"
cessation efforts, the average one-in-four success rate of multi-modality
cessation programs do not reduce smoking prevalence at a high enough

rate for cost effectiveness to be demonstrated. Even the maximum

reported success rate of 35% is inefficient tow,ard that goal.
3. Relatively few smokers are ready to quit-Despite the availability and

affordability of sponsored smoking-cessation programs, the lure of
nicotine is too strong for 60% of smokers to seriously attempt to kick the
habit in any given year. Thus, the number of longer-term and incorrigible

smokers drives the total cost of cancer care.
4. Cessation benefits are underutilized-Only half of smokers motivated to

quit will access a paid smoking cessation benefit. The rationale for

declining support is not clear and is beyond the scope of this report.
Nonetheless, these smokers are less likely to achieve the goal of

becoming cigarette-independent.
5. Measurable cancer risk persists after smoking cessation-For reasons

previously described, quitters experience a 67% decrease in lung cancer
risk over 10 years. Despite this important reduction, the absolute risk to
this group remains significant.
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Neither current nor impending science will influence limitation five. The other

constraints, however, may be loosened by improvements in, or increased

utilization of currently available smoking cessation resources. More effective

therapy for lung cancer would both improve average longevity and shift the
financial balance toward smoking cessation. The other drivers of prevention

cost-effectiveness relate to the success and utilization of cessation programs and

smoking avoidance. All are discussed in the balance of this thesis.

Obstacles to Comprehensive Smoking Cessation Efforts
Broad-based smoking cessation efforts require two components:
1. Activation and engagement of the smoking public
2. Deployment of tools for overcoming the physical, social and psychological

addiction to cigarettes.

Specific drivers within each of these elements provide the needed force to
enable cessation. Each driver has inherent advantages, limitations, resource

requirements and counter-forces. A discussion of the tools for smoking
cessation therapy has previously been discussed. The obvious shortcomings of

most forms of therapy include cost, social stigma, effectiveness and tolerability.
Suffice it to say that improvement in therapy for tobacco addiction will enhance

the success rate.

Cessation treatment is also unlikely to be consistently effective if smokers are

not truly motivated to quit. Considerable attention has been addressed to

identifying and targeting those within the cohort who are actively prepared to

9O

undergo smoking cessation 143. Approaches to smoker activation may be
described as follows:

Personal efforts
Direct-to-consumer promotional efforts, including not for profit,

government-sponsored and commercial activities
Clinician-based efforts

Employer and insurance-sponsored efforts

Government and non-government public health efforts
Taxation and other legislation

Each of these approaches has a specific message and audience. Some

attempt to appeal to a segment of smokers (such as youth, women or a specific
ethnic group), while others are directed to the entire cohort. Often recruitment

efforts are broadcast to an entire population, smokers and non-smokers alike.
Each type of effort is restricted by the availability of resources or competing

agendas. Some are relatively cost-effective while others are either relatively
ineffective or inefficient.

Personal efforts
Individual attempts to induce smoking cessation include family

intervention and self-motivation. These efforts are mildly effective, and are often

143

Goidberg, D., Hoffman, A. and Anel, D. Understanding People Who Smoke and How
they Change: a foundation for smoking cessation in primary care, part 1. Disease-amonth. 48:6. 385-439. 2002.

91

unfocused. They attempt to force activation rather than leverage personal
readiness. Within the data presented above are statistics that demonstrate the

lack of efficacy of unguided, unaided efforts. Exceptions to this rule may be
smokers who become activated during acute or decompensated chronic illness.

Direct-to-consumer (DTC) efforts

DTC messages are those provided in print and the audiovisual media.
Included are paid advertising, public service announcements and other

publications and broadcasts. Although such messages are effective for
commercial ventures, most share a common inefficiency; they are difficult to

target. Smokers in particular, are such a heterogeneous group that it is hard, if
not impossible, to direct a message specifically to them. By definition, the

message will be largely irrelevant to more than three-quarters of the audience.
The smokers that receive quit messages are also a mixed group. This approach

cannot be concentrated on those who are activated and ready to quit.
There is also evidence that DTC medical advertising has a limited and transient
impact on consumers. This phenomenon has been cited in the dramatic

decrease in utilization of total body CT scans for cancer screening in the U.S.

over the past two years 144.
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Clinician-based efforts
Medical

practitioners have unique opportunities to convey the best possible

message directly to smokers. They further have the ability to both activate
smokers who are not ready to quit and provide immediate therapy to those who

are motivated. By definition, medical practitioners have direct access to those
most likely to quit, patients with acute smoking-related illness. It has been
demonstrated that brief advice provided during routine office visits are at least as
cost-effective as other preventive medical practices, such as the treatment of
mild to moderate hypertension or

hypercholesterolemia4.

Despite claims to the contrary, neither capitated nor fee-for-service insurance

plans provide physicians with reasonable incentives to provide comprehensive
smoking cessation services Two ICD-9 codes are used for treatment. 305.1 may
be used for tobacco dependence. V15.82 designates history of tobacco use. By
and large, the existing reimbursement structure favors disease treatment over

complex, often time consuming primary prevention efforts.

Employer and insurance sponsored programs

For most employers, medical services may be considered partly a tandem
effort between business and insurer. Employers’ interest in smoking cessation
has several sources. First is the recognition that smoking-related illness impairs

productivity and drives medical and disability costs, a factor that was considered
in the introduction of this thesis. Second is an attempt to differentiate a business
145
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as an "employer of choice" by providing smoking cessation therapy as part of a
health maintenance package. Finally corporate benevolence, though far from
universal, may influence decisions in support of smoking cessation efforts.

Countering these influences is the employee longevity factor. Given the

decades-long latent period for smoking-related illness, it is quite possible that a
smoker-employee will no longer be actively employed or connected as a
beneficiary when lung cancer is diagnosed. In this context it would run counter to

corporate fiduciary interests to fund cessation programs.
Aside from acting as the heaithcare management agents of sponsoring
businesses and individuals, the insurance industry experiences mostly a

marketing gain from smoking cessation effor[s. The increase in claims or death
benefits is underwritten into smoker’s policies. It is likely that the cost of second-

hand smoke is factored into premiums as well. Thus, the cost is passed along to

consumers, employers and governments.

Company-sponsored pharmacy benefits most often emphasize care over
prevention. Smoking cessation serves as a case in point. Bupropion in the U.S.
is available under two brand names. Welibutrin is marketed for clinical

depression, while Zyban, an identical formulation is indicated for smoking
cessation. The former brand is universally available through private pharmacy

benefit management (PBM) companies (albeit, at times with required prior

authorization), while the latter is highly

restricted, in

a recent survey, only 40% of

large employers using a PBM’s covered Zyban. The majority had no coverage
for any prescription or non-prescription cessation medication. Companies that
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included Zyban in their formularies most often limited the drug’s use through

restricted coverage, capped maximum expenditures, or enacted higher

copays4e. Non-prescription medications, such as nicotine replacement patches
are most often excluded from coverage as well, although some employers allow
for these items to be purchased with designated pre-tax funds.

There is evidence that uncovered, and even subsidized expenses for
cessation therapy may pose a significant obstacle for smokers considering

quitting, in an unpublished study at General Electric Company, a smoking
cessation program that promoted QuitNet was instituted. The cessation initiative

was marketed to 300,000 employees and spouses. The first 300 enrollees into
the program received lifetime subscriptions to the service. Subsequent enrollees

were required to pay $65, a price that was markedly discounted from retail. The

courtesy subscription limit was reached within the first 30 days of the program.

In the following 30 days, only a single eligible beneficiary signed on for the
discounted Quitnet

package147.

With virtually no cost, employers may restrict the locations at which

employees may smoke and the time available to do so. Evidence indicates that
workplace smoking bans are associated with higher rates of cessation attempts,
lower rates of relapse in smokers who attempt to quit and a 10% decrease in

smoking prevalence among employees. 148’149

146

Jay, G. Medco Health Solutions. Personal communication.

147

Doran, B. General Electric Company. Personal communication.

148

Farkas, A.J. et. al. The Effects of Household and Workplace Smoking Restrictions on
Quitting Behaviours. Tobacco Control. 8; 261-265. 1999.

95

Government and government-funded public health efforts

As the 21 st century begins, a debate has emerged on the state of public
health in the U.S. The CDC, OSHA, FDA and other government agencies

promote the continued potency of their programs. There is a counter view,
however, claiming that public health directed prevention activities in the United

States have been severely curtailed in recent decades and are grossly
inadequate. The Institute of Medicine’s reports, The Future of Public Health, and
The Future of the Pubfic’s Health in the 21 t Century, argue that, "this nation has
lost sight of its public health goals and has allowed the system of public health
activities to fall into disarray".

’’

In the U.S. only 9% of all health care

expenditures, including the budgets of The National Institutes of Health and the

Centers for Disease Control and Prevention, are directed toward public health
efforts. 5 At present a disproportional allocation of public health resources is
earmarked for tertiary prevention and administration. At the state level (1996

figures), two-thirds of spending is for personal health services, whereas spending
for population-based primary prevention services is only one percent of total

,49
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health care expenditures.

In addition to diverting essential funds from primary

prevention programs, this disparity has led to confusion among many between
public health services and welfare. 154
These limitations clearly extend to smoking cessation programs, in 2002,
for example, only two states offered Medicaid coverage for all recommended
medication and counseling treatments for tobacco dependence, whereas

states covered no tobacco-dependence treatments. 1

Taxation and other legislation

As detailed in table 7, The United States has by far the lowest tax rate for
cigarettes in the industrialized world.

1.3
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United
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Total Taxes Tax Rate
$14.44
$11.43
79.2%
$9.61
$12.09
79.5%

Price

Norway
United Kingdom
United States-highest
Ireland
Australia

Hong Kong
New Zealand

Austria

Luxemburg
Italy
Greece

$8.51
$7.67
$7.59

$6.73
$5.28
$3.94
$5.52
$5.20

$7.27

Finland
United States-lowest

Belgium
Netherlands

$3.90

$7.41

Canada
Denmark
Sweden

Germany
France

$10.16

$7.20

$5.88

$6.95
$6.75
$6.25
$5.28
$5.27
$5.02
$4.89
$3.71
$3.7
$3.68

$4.90
$5.13
$1.06
$3.63
$3.98
$3.73

$3.42

$3.57

$2.51
$2.51
$2.75

Spain

$3.16

$2.48
$2.25

Portugal

$3.11

$2.51

79.0%
68.9%
51.9%
74.5%
71.6%
81.7%
70.5%
79.0%

68.9%
75.5%
74.4%
73.0%
67.7%
74.7%
74.7%
72.8%
71.2%
80.7%

Table 7. Relative cost and tax rate for cigarettes in various industrialized countries. U.S. rates
include federal state and city taxes. The highest rate is for New York, lowest for Kentucky. All
CAD $1.00=USD $0.64). Adapted from
prices are in 2002 Canadian
Global Cigarette Taxes and Prices

Dollar,s(conversion

This reality clearly impacts on reduction and cessation efforts. Evidence from

multiple studies suggests that smoking prevalence and cessation rates are

directly linked to the cost of a pack of cigarettes.

157.158.
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in cigarette taxation in 1989 was associated with a decline in per capita cigarette

consumption of 2.72 packs/year relative to the concurrent decline in total U.S.

smoking. This improvement decreased to 2.05 packs/year when the program

was scaled back in 1992 sg. Even in selected subpopulations, this relationship
holds. Among pregnant women, a 10% increase in the price of cigarettes has
been associated with a 7% decrease in smoking prevalence. 1 The benefits of

higher cigarette taxes go beyond direct disincentives. Additional revenue may be
used to improve funding of public and private smoking cessation programs. Two
theoretical shortcomings of increased taxation may exist, however. First is the

possibility that raising the cost of a pack of cigarettes will to some extent
decrease the rate of personal consumption without impacting cessation.

Smokers may drift into lower risk categories by cutting down, but will not receive
the full benefit of quitting. Second, increasing revenues from cigarette taxes may

foster a government reliance on propagation of the U.S. tobacco industry.

At

some point the government may become more dependent on cigarettes than the
public it seeks to protect.
The U.S. government has traditionally supported tobacco farming through
direct subsidies and tax incentives. This trend, however, may be receding. A
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recent government-sponsored cigarette control effort used farm subsidies to

encourage conversion from tobacco to other crops. (The Flake-Van Hoilen
amendment to legislation approved in July, 2004 prohibits the use of taxpayer
funds for tobacco farm buyouts). It is unlikely, however, that these efforts will
decrease the availability or increase the cost of cigarettes. The U.S. cigarette

industry has already begun to convert from domestic to foreign tobacco as a cost
containment strategy. ;62

The CDC and other public health groups have realized limits to the
effectiveness of voluntary population-based efforts. Recently they have begun to

actively work with their legislative partners on an active program of developing
and implementing a framework as a tool for preventing chronic diseases and

addressing the growing epidemic of obesity, heart disease, stroke, and other
chronic diseases and their risk factors. It is hoped that these efforts will

eventually lead to legally mandated prevention programs including smoking
cessation and obesity deterrence. 63 The California tobacco control program as

well as designed studies strongly suggest that restricting the locations where
individuals may smoke decreases exposure to second hand smoke, decreases
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per capita consumption of cigarettes, increases the likelihood that smokers wit!

attempt to quit and decreases the prevalence of smoking. :764’e

What Needs to be Done to Reduce the Toll of Lung Cancer in the U.S.
1. Provide Insurance

Coverage and a Framework for Screening High Risk

Individuals at High Risk for Lung Cancer

Figure 14 demonstrated that survival from lung cancer is directly related to stage
at diagnosis.

Thus it may be inferred that earlier diagnosis is associated with

more favorable outcomes.

Application of this theory, however, is hindered by

the question of who and how to screen. Expansion of most medical screening

programs has been hampered by inadequate predictive values of available tests
applied to a general or at risk population. This limitation is certainly true for
smokers and smoking-related illness. Multiple studies have demonstrated a tack
of survival benefit for individuals diagnosed via chest X-ray or standard sputum

cytology and these tests have not been recommended for broad screening

purposes among smokers. 6 Compelling data, however, now favors the use of
limited testing for cardiovascular and pulmonary disease in this high-risk
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population. The United States Preventive Services Task Force, for example,

now recommends abdominal ultrasound scans for elderly smokers and estimates
that 3,000 lives could be saved each year by the detection and resection of

smoking-related abdominal aortic aneurysmseT.

An accumulating body of

evidence, including the Early Lung Cancer Action Project (ELCAP) suggests that

CT screening of long-term smokers could more accurately diagnose lung cancer
and could identify tumor nodules at an earlier stage. The ELCAP data is striking.

In that series, 96% of CT diagnosed cancers were resectable and 85% were

Stage !. Use of this technology in high risk individuals may be clinically effective,
associated with relatively few unnecessary invasive procedures and is cost-

effective. Coupling CT scanning with automated quantitative image cytometry,
which detects gross genomic aberrations, may further improve diagnostic

yield. 168,169, i70

2. Improve Lung Cancer Treatment

Use of agents like gefitinib and erlotinib may offer a glimpse of the potential of
"personalized medicine" to transcend the existing lung cancer survival plateau.

Clearly, the promise of the field of genomics is extraordinary. Genetic alterations
le7
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in various progression stages of lung cancer cells have been studied. These

alterations can be regarded as molecular footprints representing the individual

processes within the transition to cancer. 7 Thus, advances in genomics may
lead to novel therapies that will have an impact on the survivability of lung

cancer. More likely (at least over a shorter term), however, is the identification of
individuals at genetically increased risk for lung cancer and pre-treatment
selection of patients most likely to respond to currently available therapy, such as

EGFR’s. For the former group, aggressive avoidance of controllable risk (such
as smoking and enhanced screening) could result. In the latter, patients who are

unlikely to benefit from potentially toxic therapy may be spared exposure.

Gene therapy offers the promise of previously unheard of forms of treatment.
Development of a mechanism for repairing smoking related nuclear damage or
inserting healthy tumor immunotherapy genes into cells could revolutionize care.

Although no practical breakthroughs against lung cancer can be reported to date,
an estimated 60% of gene therapy trials are now aimed at cancer therapy 7.
Other novel treatments including targeted therapy and vaccine-mediated
stimulation of the immune system are being actively studied for use in both small

cell and non-small cell lung cancer. Their potential is significant.

Regression analysis cannot predict the future. Certainly, continuing

advances in diagnostics, cytotoxic chemotherapy, radiation therapy, and surgical
techniques will have an impact, it remains impossible to predict whether the next
171
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breakthrough in conventional therapy will elevate the benefit of treatment above
the current plateau. Even less certain is the future impact of the novel therapies

including anti-angiogenesis, gene therapy, monoclonal antibodies, and
genomics. Compounding this uncertainty is the question of whether new

technology will be affordable or even available to the entire at-need population.

3. Improve the Effectiveness of Smoking Cessation

Programs

Advances in the science of addiction may yield additional mechanisms
and therapies for smoking cessation. In addition to the development of new

products, a shift from poorly effective and single-modality treatments to those

proven to be most effective should increase the quit rate. Smokers are not a
homogeneous group. Variations in psychological, physiological, social and
demographic forces affect the suitability of each type or combination of therapy.

Even such basic distinctions as gender affect treatment outcomes for different
modalities. Unlike men, women most often cite potential weight gain as a major

obstacle for smoking cessation. In addition, the likelihood of success of
cessation therapy, and especially nicotine replacement, has been linked to the

female menstrual cycle 173. Further study is required to determine subsets of
smokers for whom the effectiveness of specific combinations of treatment
modalities would be most effective. Healthcare practitioners require additional

training on the selective use of each type of cessation therapy. Additional effort
173
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should also be given to determination of the utility of non-traditional forms of
cessation therapy such as aversion therapy and homeopathic care, many of
which have demonstrated some degree of effectiveness.

Hypnotherapy, for

example, has produced 20-40% 6-month quit rates among well-motivated patient

groups. Even higher success rates have been associated with individualized
induction, greater clinical experience, and greater patient hypnotizability 74.

Acupuncture may also be modestly effective for smoking cessation. A review of
randomized control trials for this modality appears in table 8.
4

Table 8. Summary of studies of acupuncture versus sham for effectiveness in smoking cessation.
Adapted from Villano and White. 75

4. Specifically target "activated" smokers for cessation efforts
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As referenced in this thesis, smoking cessation programs are a modestly
cost-effective alternative to lung cancer treatment. This differential can be further

improved by targeting smokers (as opposed to broad marketing campaigns that
reach smokers and non-smokers alike), those who are motivated to quit, and

especially smokers with acute or recurrent illness.
Research discussed previously suggests that broad marketing campaigns
that reach both the smoking and non-smoking populations are relatively

inefficient tools for promoting cessation programs. Directed outreach, even to

healthy, poorly motivated smokers may offer an important resource advantage.
Consideration should be given to providing concentrated outreach in areas and

groups where smokers are likely to congregate. These include the following:
Geographic regions where smoking is highly prevalent
"Smoking rooms" in offices and smoking-permissible areas in
public buildings.

Bars and taverns
Smoking-permissible rooms in hotels
Hospitalized smokers are among the most highly motivated to stop.

Using only nicotine replacement therapy, they are much more likely to quit and
remain off cigarettes for 6 months or more than the smoking population in

general. Nurse led intervention has been associated with a 50% 12-month quit

rate among patients hospitalized with coronary artery disease 176,177. As
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referenced previously, the elderly and smokers with underlying obstructive

pulmonary disease still experience a substantial lung cancer risk reduction after
cessation.

Statistical opportunity seems to exist up to the development of

irreversible oncogenic mutation. Maximum effort should be directed at prompting

acutely ill smokers to quit. This may be achieved through physician offices, by
providing materials and programs tailored to smokers who are under evaluation
or care for acute or chronic (smoking or non-smoking related) illness.
Pharmacies may be another contact point for ill smokers. Adult patients

receiving prescriptions for medications for acute respiratory infections or COPD

should receive information on how to access smoking cessation services,
including the scope of available insurance benefits.
Hospitals should actively identify inpatient and outpatient smokers and

designate a counselor to recruit them into cessation programs. (Hospitalization
alone provides a springboard into abstinence. Often patients will traverse

physical withdrawal during their stay). Pilot smoking cessation programs were

begun in hospitals over 20 years ago. Still, in a recent survey, only 30% of
hospital web sites contained information relating tro smoking cessation programs
and only 47% of hospital switchboards had smoking cessation programs
available for phone inquiry 78’79. Electronic medical records systems should be
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adapted to flag smokers at the time of admission, such that the counselor may

identify and provide services to all. The medical standard of care should dictate
that all smokers receive counseling and the opportunity to begin cessation

therapy prior to hospital discharge.
Expensive smoking cessation resources, such as pharmacotherapy
should be concentrated on smokers who are most likely to respond to their use.

An algorithm for the efficient use of pharmacotherapy as part of an overall
smoking cessation strategy was previously provided as figure 11.

6. Concentrate Smoking Cessation Efforts on

Young Smokers

Smoking cessation does not eliminate the risk for lung cancer for several

reasons. An early cancer, though not clinically apparent, may be present at the
time of cessation. Taken a step earlier, irreversible oncogenic mutations may

have occurred prior to cessation that will generate lung cancer, irrespective of
removal of the causative irritation. It thus makes complete sense to concentrate

resources on the subpopulation of smokers for whom the potential for cancer
avoidance is greatest. Activating and identifying young smokers who are
motivated to quit would further improve program efficiency. A scheme for

focusing cessation efforts to this group appeared as figure 20.

Beyond the promotion of cessation programs, a second strategy for
preventing, minimizing, and terminating cigarette use in young people is to raise
tobacco excise taxes. Studies have shown that youth, minorities, and low-
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up, at each patient encounter a. Still, the current clinical model favors high
volume, short visit care. This dynamic is poorly suited to the intensive
evaluation and counseling required for highly effective smoking cessation

therapy. Several changes are needed to improve physician-led cessation efforts.

They include the following:

Improve payment incentives provided to medical and mental health
practitioners for cessation counseling and treatment
Provide additional training to allow clinicians to identify activated smokers

and match individual smokers to the best personal cessation strategy

Increase the availability of tools and templates for clinician use

Promote the use of electronic medical records that can identify and track
smokers and cessation efforts

Create the expectation that cessation therapy will be considered the
medical standard of care for all smokers seeking medical attention

7. Improve Insurance Coverage for Smoking Cessation Programs
This thesis adds data to the case that the cost of fully funded,

multimodality smoking cessation programs is less than the cost of care for lung

cancer. Clearly, full coverage of tobacco dependence treatment has been shown
to be an effective and relatively low cost strategy for significantly increasing quit
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attempts and quit rates. 83 Also evident in this review is the demonstrable
advantage of muiti-modality comprehensive therapy over single agent or "cold

turkey" approaches. Basic health insurance should provide not only skeleton

coverage, but comprehensive reimbursement for practitioner-based activation
efforts, counseling, and proven pharmacotherapy (prescription and OTC). The
Public Health Service-sponsored Clinical Practice Guideline, Treating Tobacco

Use and Dependence, and the Community Preventive Services Task Force
recommend that all insurers provide tobacco cessation benefits that do the

following:

Cover at least four counseling sessions of at least 30 minutes each,
including proactive telephone counseling and individual counseling.

Cover both prescription and over-the-counter nicotine replacement
medication and bupropion

Provide counseling and medication coverage for at least two smoking
cessation attempts per year.
Eliminate or minimize co-pays or deductibles for counseling and

medications, as even small copayments reduce the use of proven

treatments.

Coverage should be provided for smoking cessation and tobacco
dependency counseling even in the absence of a related medical condition.
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Health plans should further promote physician efforts by providing quality
incentives for their efforts.

8.

Improve Funding of Government-sponsored Smoking Cessation

Programs
The rationale for government sponsorship of smoking cessation programs
as a part of public health policy is even more compelling than the argument for
private insurance coverage. The age at which smoking most often begins and
the several decade lag between onset of smoking and diagnosis of lung cancer

mean that this illness disproportionately affects older Americans. Thus, the
burden of paying for lung cancer lies largely within the Medicare program. As

demonstrated in this thesis, each dollar of smoking prevention will yield a savings
of roughly 7.5% in lung cancer treatment expenses alone. At no additional cost
the public will experience savings in treatment of other smoking-related illnesses

including obstructive lung disease, cardiovascular disease, stroke, and multiple
other malignancies.
Under current government guidelines, Medicare managed care programs

are supposed to encourage patients to quit smoking. Unfortunately, that
mandate has not routinely translated into coverage for smoking cessation

treatments. As of 1998, 13% of all enrollees into a Medicare funded managed
care plan were active cigarette smokers 184. Given the data supporting the health
effects of cessation in the elderly, this group represents a large opportunity for
184
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improved geriatric health and cancer avoidance. Traditional Medicare and
Medicare managed care programs should provide full smoking cessation

benefits.

9. Further Encroach on the Locations Where Smoking is Allowed

Smoking is a threat not only to the individual who uses cigarettes, but
also to the public exposed to environmental tobacco smoke. This reality provides

a basis for restricting public locations where cigarettes are consumed. Cigarette
smokers should not be accommodated in private or public buildings. Even where
allowed by law, smoking rooms and other designated areas should be

discouraged. Contrary to the concerns of bar and restaurant owners, banning
smoking from public establishments does not decrease business. Rather,

patrons are more likely to frequent establishments that are smoke free8.
Although there may be practical limits on the environments and situations in
which smoking may be prohibited, surprising leeway exists in many areas, in 20

states it is legal for an employer to mandate that employees not smoke on and
off the job. One employer placed such a restriction, with fines for employees

testing positive for nicotine who refused to commit to counseling or personal quit

efforts. As a result, approximately 20 employees (out of a workforce of 200)

completely discontinued all use of tobacco products. 86 Restrictions on smoking
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even induce reduction and cessation in teenagers. This benefit speaks to
previous points on the importance of addressing young smokers and should
further drive this effort a7

10. Increase Business Efforts Toward Smoking Cessation

Employers must not only recognize smoking cessation as a cost-savings

strategy, but must also identify opportunities to provide effective, employeeacceptable cessation resources. Several touch points and strategies have been
identified 88".

Smokers who wish to stop smoking and whose needs include access to

high quality treatment (counseling, education, and drug therapies) need
assistance in paying for treatment, and a supportive work environment

and policies.

Smokers who are not ready to stop smoking should be motivated through
incentives, disincentives, education and workplace policies.

Recent ex-smokers require follow-up to prevent relapse
Nonsmokers should not be subjected to environmental tobacco smoke
Supervisors and managers require practical guidelines for implementing

smoking policies and addressing conflicts between smokers and
nonsmokers, as well as resources to which they can refer employees who
wish to quit smoking.
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Smokers may be enticed or assisted with quitting as part of off-work

benefit or communications programs.
There are several inherent advantage of employers’ participation in smoking
cessation efforts. Businesses have the organizational structure to identify and
communicate with smoking employees. They may use the leverage of peer-

pressure; over two-thirds of all employees are non-smokers. Employers certainly
can leverage purchasing power to reduce the cost of cessation efforts.

Non-proprietary educational and cessation materials should be promoted
for business customization and use. Business leaders need to recognize the
value of smoking cessation programs and need to access (or develop in house)
the tools to encourage (or force) their employees to quit.

Employees also bear part of the responsibility of smoking cessation in the
workplace. Unions should not view smoking restrictions as an adversarial

strategy. Rather, they should embrace this effort as an opportunity for a
cooperative effort for employee health and safety.
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Section V-Conclusion
-Economics has been described as the science of allocating scarce resourcesDavid M. Eddy, M.D. PhD. 1981

Americans, as both individuals and a society have become significantly

dependent on cigarette smoke. It has become habit to 60,000,000 citizens and is

ingrained in our culture. Although recent trends in smoking prevalence and the
potential for breakthrough treatments in lung cancer are cause for optimism, the
toll from this disease remains staggering. This thesis has added to an
impressive body of evidence suggesting that primary prevention of lung cancer
and other smoking-related illnesses could be a more cost-effective strategy for

managing the financial burden of lung cancer than patient care. It has shown the

poor correlation between modern medical advances and survival and has
documented the potential for savings associated with the provision of

comprehensive, multi-modality smoking cessation tools relative to surgery,
radiation and chemotherapy.

It would be unfair to claim that cigarette smoking continues unabated in
this country. Legislation, changing attitudes, improved cessation methods,

litigation, and cigarette cost increases continue to separate individuals from a

highly addictive habit. Even more dramatic than the overall decline in prevalence
has been the recent decrease in smoking behavior among our youth (figure 21).

Although the slope has decreased in recent years, there is every reason to
believe that the absolute decline in smoking prevalence witnessed over the past

decade will continue into the future.
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